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Re´sume´ en franc¸ais
La radiothe´rapie par modulation d’intensite´ (IMRT) est une technique actuelle de traitement des tumeurs cance´reuses,
en constante expansion et en constant de´veloppement. La radiothe´rapie guide´e par image (IGRT) permet de ve´rifier
que le patient est correctement positionne´ avant de de´livrer une fraction de dose. La tomothe´rapie est une tech-
nique d’IMRT consistant a` de´livrer la dose he´lico¨ıdalement avec un faisceau fin (1 a` 5 cm). Elle est commercialise´e
par Accuray sous la marque TomoTherapy®. Ce syste`me posse`de un de´tecteur de tomodensitome´trie me´gavolt
(MVCT) lui permettant d’imple´menter l’IGRT.
Les recommandations internationales pre´conisent de ve´rifier l’exactitude de la dose de traitement. Une dose
de qualite´ maximise la probabilite´ de controˆler la tumeur tout en minimisant le risque de dommages aux tissus
sains, donc maximise les chances de re´mission sans complication du patient. La pratique la plus courante consiste
a` mesurer syste´matiquement une fraction de dose avec un film radiochromique ou une matrice de de´tecteurs
place´e dans un fantoˆme homoge`ne avant de commencer a` traiter le patient. Ce protocole d’assurance qualite´ (QA)
ve´rifie dans un fantoˆme l’exactitude avec laquelle l’unite´ de traitement de´livre la dose. Cependant, il ne ve´rifie
pas l’exactitude avec laquelle le syste`me de planification du traitement (TPS) a calcule´ la dose dans les diffe´rentes
structures anatomiques du patient. De plus, ce protocole ne permet pas de pre´dire l’e´cart entre dose de´livre´e et
planifie´e dans les organes a` risque et volumes cible du patient. Afin de re´pondre a` ces besoins, ce travail de the`se
s’est focalise´ sur la ve´rification de la dose calcule´e par le TPS et sur l’assurance qualite´ de la de´livrance (DQA) de
la dose en tomothe´rapie.
Dans un premier temps, un logiciel de calcul inde´pendant de la dose, CheckTomo, a e´te´ mis a` jour suite a` la
commercialisation de TomoEDGE. TomoEDGE permet une meilleure conformation longitudinale de la dose,
pre´servant ainsi les tissus sains situe´s en avant et en arrie`re de la tumeur. CheckTomo a e´te´ teste´ sur des plans
TomoPhant (utilise´s pour des mesures routinie`res de QA sur fantoˆme) avec maˆchoires dynamiques et sur 30 plans
cliniquement accepte´s. Sur les plans TomoPhant, des erreurs de calcul de dose allant jusqu’a` 5 % ont e´te´ observe´es.
Les plans cliniques ont e´te´ soumis a` des tests de taux de succe`s du γ-index (γ-test). Avec des tole´rances de 3 %/2 mm
(normalisation globale), le taux de succe`s e´tait infe´rieur a` 95 % dans 53 % des cas. Les re´sultats des γ-tests sur les
plans avec maˆchoires dynamiques e´taient en moyenne les meˆmes que sur des plans avec maˆchoires statiques. Ceci
tend a` indiquer que la faible exactitude globale de CheckTomo ne de´pend pas – ou pas uniquement – du mode des
maˆchoires. Finalement, une erreur de dose globale de 3 % a e´te´ applique´e aux plans. Dans ce cas, tous les plans ont
e´choue´ le γ-test a` 3 %/ 2 mm avec un seuil de succe`s de 95 %. On conclut a` une haute sensibilite´ de CheckTomo
dans le cas d’une erreur globale.
Dans un second temps, les temps d’ouverture des lames (LOT) du collimateur ont e´te´ mesure´s en ligne puis la
dose de´livre´e a e´te´ calcule´e dans les images de planification du patient. Sur les unite´s de tomothe´rapie, le de´tecteur
MVCT mesure la fluence de photons sortant du patient pendant les traitements. Un algorithme de mesure des
LOTs a` partir des donne´es du de´tecteur a e´te´ de´veloppe´. Pour le calcul de dose, un calculateur autonome fourni
par Accuray a e´te´ utilise´. L’algorithme de mesure des LOTs a e´te´ teste´ sur des donne´es de la proce´dure Daily QA de
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l’outil TomoTherapy Quality Assurance (TQA) et sur les donne´es de 25 plans cliniques. Les donne´es cliniques ont
e´te´ collecte´es une fois dans l’air et une fois in vivo (i.e. avec le patient sur la table). L’intensite´ du signal de´croissant
fortement avec la fermeture des maˆchoires dans le cas d’un faisceau d’une largeur nominale de 5.0 cm, il n’a pas e´te´
possible de mesurer les LOTs en dessous d’un e´cartement des maˆchoires de 13 mm. Pour les e´cartements de taille
supe´rieure et pour les faisceaux avec d’autres largeurs nominales (1 et 2.5 cm), l’algorithme s’est re´ve´le´ eˆtre robuste.
Il a permis de mesurer les LOTs sur des plans a` maˆchoires statiques ou dynamiques sans que l’incertitude ne varie
avec la taille du faisceau. De meˆme, l’incertitude de mesure des LOTs n’e´tait pas significativement supe´rieure in
vivo que dans l’air. Pour tester la faisabilite´ de calculer la dose a` partir des LOTs mesure´s, des “erreurs” ale´atoires
de LOT (suivant une distribution gaussienne) ont e´te´ ge´ne´re´es et introduites dans un plan TomoPhant. En tout,
six plans avec des erreurs moyennes respectives de −6 %, −4 %, −2 %, 2 %, 4 %, et 6 % ont e´te´ ge´ne´re´s. La dose de
chacun de ces plans a e´te´ mesure´e avec des chambres d’ionisation place´es dans un fantoˆme au niveau du centro¨ıde
des volumes cibles. Les LOTs ont e´te´ mesure´s a` partir des donne´es du de´tecteur et la dose de´livre´e a e´te´ calcule´e.
Doses mesure´es et doses calcule´es e´taient compatibles a` 0.5 %, indiquant une bonne fiabilite´ des LOTs mesure´s.
Finalement, sur des plans cliniques, une corre´lation de 0.84 a e´te´ observe´e entre la me´diane des erreurs relatives de
LOT et le changement de dose dans le volume cible. La me´diane des erreurs relatives de LOT pourrait donc eˆtre
un indicateur de la qualite´ de la de´livrance facile a` mesurer.
Un protocole de DQA base´ sur la mesure des LOTs pourrait permettre de re´duire la charge de travail lie´e a`
l’assurance qualite´ en IMRT en supprimant la ne´cessite´ de mesurer la dose de´livre´e dans un fantoˆme. Par ailleurs,
mesurer les LOTs in vivo pendant la de´livrance de chaque fraction de dose permettrait de faire un DQA de chaque
fraction individuellement. Combiner la mesure en ligne des LOTs a` un algorithme inde´pendant de calcul de dose
permettrait de re´aliser conjointement un QA de la planification et de la de´livrance. De plus, calculer la dose dans
les images journalie`res du patient permettrait de mettre en place un protocole de DQA tre`s proche de la dosime´trie
in vivo.
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Abstract
Intensity modulated radiation therapy (IMRT) is a current technique for the treatment of cancerous tumours,
constantly expanding and developing. Image guided radiation therapy (IGRT) is used to verify that the patient is
correctly positioned before delivering a dose fraction. Tomotherapy is an IMRT technique that consists of delivering
the dose helically with a fine beam (1 to 5 cm). It is marketed by Accuray under the TomoTherapy® brand. This
system has a megavoltage CT detector (MVCT) to implement the IGRT.
International guidelines recommend to verify the accuracy of the treatment dose. A dose of quality maximises
the probability of controlling the tumour while minimising the risk of damage to healthy tissues, thus maximises
the chances of complication free remission for the patient. The commonest practice is to systematically measure a
dose fraction with a radiochromic film or a detector array placed in a homogeneous phantom before starting to treat
the patient. This quality assurance (QA) protocol verifies in a phantom the accuracy with which the treatment
unit delivers the dose. However, it does not verify the accuracy with which the treatment planning system (TPS)
calculated the dose in the patient’s various anatomical structures. Additionally, this protocol does not allow the
clinicians to predict the difference between delivered and planned dose in the patient’s organs at risk and target
volumes. In order to meet these needs, the work done in the context of this thesis focused on the verification of
the dose calculated by the TPS and on the dose delivery quality assurance (DQA) in tomotherapy.
Firstly, an independent dose calculation software, CheckTomo, was upgraded following the launch of To-
moEDGE. TomoEDGE allows a better longitudinal conformation of the dose, thus preserving healthy tissues
located at the tumour’s front and back. CheckTomo was tested on TomoPhant plans (used for routine QA meas-
urements in a phantom) with dynamic jaws and on 30 clinically accepted plans. In the target volume of the
TomoPhant plans, dose calculation errors up to 5 % were observed. The clinical plans were subjected to γ-index
pass rate tests. With tolerances of 3 %/2 mm (global normalisation), the pass rate was less than 95 % in 53 % of
the cases. The γ-index pass rates on plans with dynamic jaws were on average the same as on plans with static
jaws. This suggests that CheckTomo’s overall low accuracy does not depend – or not only – on the jaw mode.
Finally, an overall dose error of 3 % was applied to the plans. In this case, all plans failed the γ-index pass rate
test with tolerances of 3 %/ 2 mm and a threshold of 95 %. We conclude that CheckTomo is highly sensitive to
global errors.
Secondly, the open times of the collimator leaves (LOT) were measured and the delivered dose was calculated in
the patient’s planning CT images. On tomotherapy units, the MVCT detector measures the photon fluence exiting
the patient during treatment. An algorithm for measuring the LOTs based on detector data has been developed.
For the dose calculation, a stand-alone calculator provided by Accuray was used. The LOT measurement algorithm
was tested using data from the TomoTherapy Quality Assurance (TQA) Daily QA procedure and data from 25
clinical plans. Clinical data were collected once in air and once in vivo (i.e. with the patient on the treatment
couch). As the signal strength decreases sharply as the jaws narrow for a beam with a nominal width of 5.0 cm,
it was not possible to measure the LOTs below a jaw aperture of 13 mm. For larger apertures and for beam with
viii
other nominal widths (1 and 2.5 cm), the algorithm proved to be robust. It allowed LOTs to be measured on static
or dynamic jaw plans without any variation of the uncertainty in function the beam width. Similarly, the LOTs
measurement uncertainty was not significantly greater in vivo than in air. To test the feasibility of calculating
the dose from the measured LOTs, random LOT ”errors” (following a Gaussian distribution) were generated and
introduced into a TomoPhant plan. In total, six plans with average errors of -6 %, -4 %, -2 %, 2 %, 2 %, 4 %, and
6 %, respectively, were generated. The dose of each of these plans was measured with ionisation chambers placed
in a phantom at the centroid of the target volumes. The LOTs were measured from the detector data and the
delivered dose was calculated. Measured doses and calculated doses corresponded within 0.5 %, indicating a good
reliability of the measured LOTs. Finally, on clinical cases, a correlation of 0.84 was observed between the median
relative LOT error and the dose change in the target volume. The median relative LOT error could therefore be
an easily measurable indicator of the dose delivery quality.
An DQA protocol based on the LOT measurement could reduce the workload related to IMRT quality assurance
by eliminating the need to measure the delivered dose in a phantom. In addition, measuring in vivo the LOTs
during the delivery of each dose fraction would allow the medical physicists to perform a DQA of each fraction
individually. Combining the on-line LOT measurement with an independent dose calculation algorithm would
allow dose calculation and delivery QA to be performed jointly. In addition, calculating the dose in the patient’s
daily images would make it possible to set up a DQA protocol very close to the in vivo dosimetry.
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Chapter 1
Introduction
Radiation therapy is a therapy technique that intends to treat cancerous tumours with ionising radiations [1]. On
common, modern radiation therapy treatment units, electrons are accelerated in a linear accelerator (LINAC) and
used either as the treatment beam or, more commonly, to generate a photon beam.
In modern radiation therapy practice, the patient care spans over several weeks and splits in two main phases
[1]: planning and treatment. The planning starts by acquiring computed tomography (CT) images of the patient.
On these, the planning target volume (PTV) and organs at risk (OARs) are delineated. The PTV is the region
that encompass the cancerous tumour and its microscopic extensions. The OARs are organs that can be damaged
by the ionising radiations and thus need particular attention, like the heart, the lungs, or the spinal cord. The
physicians issue a dose prescription to the PTV, dose constraints on the OARs, and a dose fractionation (the dose
is delivered in several fractions). Dose prescription and fractionation depend on the target region [2] and dose
constraints are organ-specific [3]. A commercial treatment planning system (TPS) is used to plan the dose delivery.
The aim is to cover the PTV with the prescribed dose while not exceeding the constraints on the OARs. The plans
must then pass dedicated quality assurance (QA) tests before it is cleared for treatment.
In most situations, the treatment phase lasts over five to six weeks. The patient comes daily to receive one
– sometimes two – dose fraction. Minutes before the dose delivery, the patient is positioned on the treatment
couch and a new set of images is acquired on-line. The daily images are compared to the planning images to
verify target and organ positions. This process is called image guided radiotherapy (IGRT). The images are
acquired in the treatment room by the radiation therapy unit itself, often using a cone beam computed tomography
(CBCT) scanner. Daily imaging also allows the clinicians to monitor notable changes of the patient’s anatomy like
inflammations, reduction of the tumour size, or weight loss [4].
The treatment safety and quality have always been major concerns in radiation therapy. A dose accurately
delivered to the patient maximises the tumour control potential while minimising the dose delivered to the OARs.
It maximises the probability of a successful, complication free outcome of the radiation therapy treatment. Safety
intends to avoid hazards with potentially severe adverse effects to the patients and the staff. Radiation therapy
centres have dedicated safety protocols and QA programmes. The work presented in this manuscript concentrated
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Figure 1.1 – TomoTherapy® H series. (Courtesy of Ac-
curay.)
on the latter.
In modern practice, inverse-planned intensity modulated radiotherapy (IMRT) has become the norm [5]. It
allows delivering dose distributions of complex shapes. Because of this complexity, IMRT requires dedicated QA
programmes and techniques.
The tomotherapy IMRT concept was proposed 26 years ago [6]. It was designed to be a fully integrated IGRT
system. It led to the TomoTherapy® system owned and commercialised by Accuray (Accuray Inc., Sunnyvale CA,
USA).
Section 1.1 presents the tomotherapy system, section 1.2 some general IMRT QA basics, and section 1.3 the QA
specificities of the tomotherapy system. Section 1.4 introduces and motivates the contributions that the present
thesis brought to the patient-specific QA in tomotherapy. It is divided in three subsections that correspond to a
dedicated scientific article in appendix.
In the context of this thesis, an independent dose calculation software was upgraded to keep up with the last
tomotherapy evolutions (§ 1.4.1). Additionally, an algorithm to measure on-line the leaf open times (LOTs) was
developed (§ 1.4.2). This algorithm was subsequently used to forward calculate the delivered dose and define a dose
accuracy predictor based on the LOT errors (§ 1.4.3). Hence, the work done in the context of this thesis covers
two QA aspects: the QA of the planned dose and the delivery quality assurance (DQA).
1.1 Tomotherapy system
The tomotherapy concept was inspired by the CT scanner. Figure 1.1 shows a modern tomotherapy treatment unit.
The patient lies on the treatment table, usually head first in supine position. The fluence is modulated by a jaw
collimator and a multileaf collimator (MLC). There exists two main delivery modalities: helical and topographic,
commercialised as the TomoHelical and TomoDirect products, respectively. A helical delivery consists of one
passage of the couch through the bore while the gantry rotates at constant speed. A topographic delivery consists
of multiple passages (usually four) through the bore. During each passage, the gantry is positioned at a specific
angle. The topographic mode is mostly used for tangential breast irradiation [7].
The radiation oncology department of the Centre hospitalier universitaire Vaudois (CHUV) possesses tow
tomotherapy units (SN137 and SN290), hereafter called TOMO1 and TOMO2, respectively.
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Figure 1.2 – Leaf open time (LOT) inaccuracies measured by the Daily QA module of TomoTherapy Quality Assurance
(TQA) on May 15, 2018.
1.1.1 Multileaf collimator and sinogram
Each tomotherapy unit is equipped with a MLC that modulates and collimates laterally the treatment beam. The
MLC is composed of 64 binary leaves which are driven by compressed air. Each leaf may open or close independently
of the others. It takes less than 20 ms for a leaf to switch from one position to the other.
For helical planning, the gantry rotations are split into 51 sectors called sinogram projections. To modulate the
fluence, the optimiser assigns an open time to each leaf at each projection. The LOTs may range from a minimum
threshold to the projection duration. The minimum LOT is defined in the jaw accelerator machine (JAM) settings.
On CHUV’s units, it was set at 18 ms.
The MLC controller relies on a set of optical sensors to check on-line the leaves state (open, close, or switching)
[8]. The controller interrupts the treatment if a leaf takes more than 40 ms to activate (i.e. to start moving) and
if a leaf takes more than 30 ms to switch state (i.e. to move completely from its close to its open position and vice
versa).
Activation and switching times are both subject to uncertainty. As a result, the actual LOTs differ from
the commended LOTs [9–12]. The LOT inaccuracies at one projection are impacted by the number of moving
leaves at previous projections, because of pressure variations of the compressed air used to drive the leaves [12].
Additionally, Lissner et al. [12] repeated a specific procedure over six months and monitored the LOT inaccuracy
of each individual leaf. They reported a maximum drift of the inaccuracy of 3 ms over the six months period.
The LOT inaccuracy is measured every morning during the checks performed by the Daily QA module of the
TomoTherapy Quality Assurance (TQA) tool (§ 1.3). The LOTs are measured by opening the leaves 8 by 8 for
50, 100, 150, and 200 ms, once at a jaw aperture of 7 mm and once at 20 mm. Figure 1.2 shows the mean LOT
measured on May 15, 2018, during the morning machine checks.
The LOT inaccuracy is referred to as the leaf latency within the tomotherapy system. It is a parameter of the
machine model in the TPS. When planning a treatment, the TPS first calculates the ideal, theoretical LOTs. At
the end of the planning process, it applies the leaf latency correction. This way, the actual LOTs are as close as
3
possible to the ideal LOTs.
1.1.2 Jaw collimator
To complement the MLC, tomotherapy units are equipped with a jaw collimator which collimates the beam lon-
gitudinally. In the first version of the tomotherapy system, the treatment could be delivered at fixed jaw apertures
only, i.e. at fixed longitudinal field widths.
In 2012, Accuray released the TomoEDGE product. It allows the jaws to move during the treatment to improve
the dose longitudinal conformity [13–15]. The possibilities offered by the dynamic jaws are likely to increase in the
future, e.g. for motion management [16].
1.1.3 Pitch
The pitch is the ratio of the table advance per gantry rotation and the field width,
pitch =
distance per rotation
field width
. (1.1)
It quantifies how much the beam overlaps with itself over successive rotations. If the pitch is smaller than 1, then
the beam will overlap with itself. In tomotherapy, the pitch is always small enough to ensure the complete coverage
of the target area. Kissick et al. [17] found that the ideal pitch in tomotherapy equals
pitch =
0.86
N
, N = 2, 3, 4, . . . (1.2)
These values minimise the thread effect, thus ensure the best dose uniformity.
1.1.4 On-board detector
The tomotherapy system uses a megavoltage computed tomography (MVCT) on-board detector (OBD) array for
on-line imaging. The OBD is made of 640 ionisation chambers filled with high pressure xenon gas. CHUV’s
treatment units have different detector models, a GE (General Electric, Boston, MA, USA) on TOMO1 and a
Hitachi (Hitachi Ltd., Chiyoda, Tokyo, JP) on TOMO2. The differences between both models are the chamber
size (1.219 and 1.250 mm, respectively), the surface to centre distance (20 and 4 mm, respectively), and the radius
of curvature (110.99 and 99.8 cm, respectively).
On the one hand, the OBD is used for imaging. On the other hand, it measures the fluence exiting the patient
during the delivery of a treatment dose fraction. The OBD raw data are collected and temporarily stored by the
treatment unit.
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1.1.5 Data acquisition system
The data acquisition system (DAS) collects the values of various machine parameters at each LINAC pulse (i.e. at
a frequency of 80 Hz while imaging and of 300 Hz while delivering a dose fraction). The data logged by the DAS
are the OBD output profile, the monitor chambers reading, the couch position, the gantry angle, and the values
of various pressure and temperature sensors. These data are stored on the on-board computer (OBC) and can be
retrieved to the operator station using the File Transfer Protocol (FTP). On the OBC, these data have a limited
lifetime. They are erased whenever a new delivery procedure is loaded on the operator station. Note that the DAS
logs neither the reading of the MLC controller optical sensors (i.e. the state of the MLC leaves), nor the value of
the jaw position encoder.
1.2 Quality assurance
In order to ensure quality and safety of radiation therapy sites and treatments, international organisations recom-
mend performing step-by-step verifications of IMRT devices and treatments [18, 19]. This consists in acceptance
tests, commissioning, routine machine QA tests, and patient-specific planning QA and DQA tests. The work done
in the context of this thesis, introduced in section 1.4 hereafter, concentrated on the patient-specific QA. The other
aspects of IMRT verification are out of the scope of the present manuscript.
Quality assurance aims to prevent errors of all types, from minor incidents to severe accidents. Ford et al.
[20] proposed to use a clinical scale to score the adverse events ranging from 0 (no harm) to 10 (death). This
scale encompasses events of all severity, classifying them by the event’s outcome. The event may have minor and
temporary, minor but permanent, disabling, life threatening, or lethal outcomes. Ford et al. [20] recommend to
classify near-misses by the severity of the harm that would have been caused had the adverse event occured. They
also warn about distinguishing between the deterministic effects resulting from an over-irradiation and the non-
deterministic effects that may result from underdosing the PTVs. In fact, a PTV unserdosage may lead to a failure
of the local tumour control, thus to a disease recurrence, and eventually to the patient’s death. They recommend
to rate underdosage with a score of 9 (i.e. consider it as a life-threatening event).
Arnold [21] pointed out two notable properties of radiation therapy errors. Firstly, the large majority of
incidents are minor. Secondly, a major accident usually impacts several patients; a major accident is usually not
a one-time event, but arises from a systematic failure. To prevent systematic failure, extensive acceptance tests,
commissioning, and routine tests of the TPS and treatment unit are required [18]. In addition, the manufacturers
have built several interlocks into their treatment systems to automatically detect and prevent possible, known
failures (e.g. output divergence, leaf positioning errors, etc.). In this context, known is important, because it is
difficult to anticipate all sources of errors. In that sense, Ford et al. [20] recommend to systematically apply safety
barriers. In other words, any patient plan should systematically go through a dedicated set of critical control
points. The choice of the control points is a topic open to debate [22, 23].
Huq et al. [23] have reported that the entire patient’s IMRT care splits into 91 steps. These steps include all
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activities needed to take the patient in charge, from entering the patient’s personal information in the hospital
database to delivering each treatment dose fraction. From that, they have identified 216 potential failure sources.
Ford and Terezakis [24] have estimated that error rate in radiation therapy was of 1 in 600, all severity combined,
over the period going from 2001 to 2008 in the US. They have reported that 94% of the errors were judged of no
clinical significance. This still left them with an error rate resulting in severe injury of 1 in 10,000 patients. Ford
and Terezakis [24] noted that the death rate in civil aviation, which is considered to be the gold standard in safety
management, is of 1 in 10 million. In Switzerland, the injury rate in road traffic accidents in 2017 was of 1 in
2,400 (seriously injured) and 1 in 475 (lightly injured). The harm caused by radiation therapy incidents during the
2001 and 2008 showed that there was room for practices improvement. It should be noted that the most severe
accidents in IMRT occurred while the corresponding relatively new techniques were being implemented throughout
western countries and that the US were the forerunners in providing IMRT at a large scale. Finally, to the author
knowledge, no severe radiation incidents have occured (respectively been reported) in the 2010’s. This may indicate
a consolidation of the QA practices and that lessons were learned from the mistakes of the preceding decade.
1.2.1 State of the art in patient-specific quality assurance
Patient-specific QA consists of all the actions taken to ensure the quality of the patient’s treatment plan and
the safety of the patient’s during their entire care. The most common checks applied in the radiation therapy
clinics world-wide were described in many publications (e.g. Alber et al. [18], Hartford et al. [19], Ford et al. [22]
and Huq et al. [23]). Most of the patient-specific QA checks are performed manually by the staff. The checks
start to roll out as soon as the patient enters the clinic. As an example, verifying the correctness of the patient’s
personal information is already a first QA check. Many QA checks aim to ensure that a plan of good quality is
being prepared, i.e. that the plan presents an acceptable balance between PTV coverage and OARs sparing. In
particular, the dosimetrists, physicians, and physicists verifiy that the structures are correctly delineated, that the
dose prescription is respected, and that the dose is homogeneous. Then, the dose calculated by the TPS should
be checked using an independent dose calculation software and the delivered dose is physically measured. These
checks are meant to ensure that planned and delivered dose correspond acceptably. The QA of the planned dose
intends to ensure by independent calculation means that the dose calculated by the TPS is accurate. Inaccuracies
could e.g. occur in heterogeneous media or in the presence of a metal implant. The DQA intends to ensure that
the treatment unit is able to deliver accurately the planned dose. Delivery inaccuracies can be caused e.g. by
inaccurate positioning of the MLC. This thesis work was focused on the planned dose QA and dose DQA checks.
It does not address the planification steps.
In that sense, the ideal QA method would measure the dose directly where it is delivered, i.e. at a specific
position within a patient’s OAR or target site. Such an in vivo dosimetry method would be the most direct
way to ensure the quality of the delivered dose. Yet, it is complicated – if not impossible – to achieve in most
treatment situations. Some groups have successfully placed thermoluminescent dosimeter (TLD) or metal-oxide-
semiconductor field-effect transistor (MOSFET) dosimeters in the patient’s natural cavities, e.g. the mouth or the
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oesophagus [25–27]. Though, many target sites are not accessible through a cavity, detector positioning is prone
to uncertainty, and the method is highly invasive for the patient. Various indirect in vivo dosimetry alternatives
exist.
Some groups measured the dose at entrance or exit points on the patient’s skin using silicon diodes, TLD,
MOSFET detectors, or radiochromic films, amongst others [28–30]. Others have implemented transit dosimetry
based on the fluence measured by an electronic portal imaging device (EPID) [31–34]. With this method, the
dose inside the patient must be reconstructed using a back-projection algorithm. A dose reconstruction algorithm
accounts for attenuation and scatter within the patient, scatter from the patient to the EPID and scatter within
the EPID itself. From the fluence measured on the EPID, the algorithm back-projects the dose in the patient
planning or daily CT images. Recent studies showed the development of commercial solutions and spreading of
EPID-based in vivo dosimetry [35].
The same results may be achieved by forward calculating the delivered dose. For this method, a fluence map
– or machine parameters allowing a fluence map to be rebuilt – must be collected on the machine while the
dose is delivered. Then, the dose can be forward calculated on the patient’s planning or daily images using a
dose calculation model, ideally independent of the TPS (e.g. a Monte-Carlo or convolution superposition (CS)
algorithm).
Not all centres have implemented in vivo dosimetry for IMRT treatments, but most – if not all – have a
dedicated pretreatment DQA protocol. The commonest method consists in measuring the delivered dose with a
detector array in a water equivalent phantom. The measured dose is compared to the dose distribution calculated
in the phantom by the TPS. The accuracy of the measured dose is evaluated using a specific metric, often a γ-index
pass rate (§ 1.2.2).
Phantom-based QA protocols have some drawbacks. First, the phantoms are cumbersome and need to be
positioned accurately on the treatment couch. This implies acquiring and registering a set of positioning images
for each patient QA, which is time consuming. Also, the array detector response may be angular dependent [36,
37]. Moreover, a phantom-based QA provides no information of the discrepancies between planned and delivered
dose in the patient’s OARs and PTVs. Finally, such protocols constitute in fine DQA tests. They do not verify
the accuracy of the dose calculated by the TPS in the patient’s anatomy. They do verify the accuracy of dose
calculated in the phantom, though calculating the dose in a homogeneous medium does not much challenge the
TPS algorithm. Ideally, independent dose calculations should be conducted in parallel to phantom-based DQA to
ensure the accuracy of the dose calculated by the TPS.
By consensus, pretreatment IMRT DQA is considered to be a safety barrier [20]. It should prevent errors to
propagate through the workflow. Huq et al. [23] noted that the actual QA practice is primarily focused on the
treatment device and does not address the question comprehensively. In particular, the author notes that many of
the accidents that occured during the 2000’s were related to a lack of staff training and communication. In that
sense, the appropriateness of the current phantom-based DQA practice is subject to debate [22, 23]. Huq et al.
[23] recommend to address the QA more comprehensively. They propose a comprehensive framework to analyse
7
the radiation therapy workflow, identify the critical points, and quantify the related risk.
Ford et al. [22] showed that the pretreatment phantom-based DQA has a poor effectiveness in catching errors.
They analysed a batch of reported high-severity near-misses. The author graded the incidents following the Autorite´
de Surete´ Nucle´aire (ASN) scale and considered incidents with a score greater or equal to 4 (thus “accidents” in
the ASN scale). The IMRT DQA caught only around 1.4 % of them. This should be no surprise, because the
pretreatment DQA cannot catch an error occurring during the planning process, like a PTV being poorly delineated.
Ford et al. [22] publication should not lead the reader to conclude of the uselessness the pretreatment DQA. Firstly,
Ford et al. [22] analysed only its effectiveness in detecting high-severity incidents (grader of 4 or 5 on the ASN
scale). Though, it is also desirable to avoid incidents of grade 2 or 3. Secondly, they did not address the PTV
underdosage problem, because target underdosage does not lead to deterministic outcomes, thus does not enter the
ASN scale. Yet, underdosage is considered to be a potentially lethal incident by some of the same authors [20]. As
we will see latter, the tomotherapy system can deviate from the planned dose by more than the 5 % recommend
in the International Commission on Radiation Units and Measurements (ICRU) report 50 [38] when suboptimally
used.
Beyond this, both Ford et al. [22] and Huq et al. [23] have pointed out that the patient-specific QA consumes
a lot of resources and puts a lot of pressure on the staff.
1.2.2 γ-index dose comparison metric
The γ-index is a widely used dose evaluation metric proposed by Low et al. [39] in 1998. It is used to compare a
measured or calculated dose distribution against a reference. Considering a point of coordinates re and of dose De
of the evaluated distribution, the problem is to know whether there is a point of the reference distribution that
is in the vicinity of re with simultaneously a dose close to De. This implies combining dose difference (DD) ∆D
and distance to agreement (DTA) ∆d tolerances. The problem can be interpreted as determining whether a point
of the reference distribution is located within the ellipse centred in (re, De) and of radii ∆d and ∆D (formally, a
four-dimensional hyper-ellipsoid). This condition can be written as
γ(re, De) = min
(√
|re − rr|2
∆d2
+
|De −Dr|2
∆D2
,∀ rr
)
6 1. (1.3)
rr is a point of the reference dose distribution. This equation is the γ-index test of point re. γ(re, De) is the point’s
γ-index. If the condition is fulfilled, then re is considered to have passed the γ-index test. The whole distribution
is then evaluated by calculating the γ-index pass rate, i.e. the relative number of points with a γ-index smaller
than 1.
The γ-index evaluation of dose distributions is a balance between the DD and DTA tolerances. If the dis-
tance to agreement is large, then the dose difference must be small. And vice versa. This approach allows the
medical physicists to evaluate jointly flat dose and dose gradient regions. In a flat dose region, the γ-index tests
predominantly the dose level accuracy through the DD tolerance. Reciprocally, in a dose gradient region, it tests
8
predominantly the gradient correct location through the DTA tolerance.
The difficulty with the γ-index resides in choosing the tolerances and interpreting the results. The American
Association of Physicists in Medicine (AAPM) Task Group 218 issued recommendations [40] concerning the toler-
ances and pass rate thresholds to apply to measurement-based QA verifications. Tolerances and pass rates depend
on the type of test (physical or clinical) and of detector (ionisation chamber, array, etc.). In particular, the test
will have a different sensitivity depending whether the DD is defined locally (in function of the dose De of the
point to evaluate) or globally (in function of the maximum dose of the evaluated or reference distribution). Also,
points in the low dose region will bias the pass rate if the dose tolerance is too high. They should be excluded from
the statistics, the recommendation being to neglect all points below 10 % of the dose distribution maximum [40].
Finally, the acceptable pass rate threshold must be determined to accept/reject a plan.
The performance of tests based on the γ-index has been extensively discussed in the literature [41–49]. Some
authors have studied the correlation (or lack of) between the γ-index pass rate and the plan quality (e.g. the dose
coverage of the PTV). Others have studied the sensitivity and specificity of the γ-index pass rate test. They reported
failures to detect or highlight clinically relevant errors. Therefore, alternatives to the γ-index were proposed. In
particular, Zhen et al. [41] proposed to turn to metrics based on the dose volume histogram (DVHs). Stojadinovic
et al. [48] proposed a divide-and-conquer approach of the γ-index by analysing high dose, dose gradient, and low
dose regions separately.
1.3 Quality assurance in tomotherapy
Booklet no. 9 of the European Society for Radiotherapy and Oncology (ESTRO) provides specific guidelines for the
verification of the helical tomotherapy system [18]. The AAPM set up a task group who issued recommendations
for machine and patient-specific QA in helical tomotherapy [50]. Machine QA tests were also extensively presented
and discussed by Fenwick et al. [10].
TQA is a tool to check the tomotherapy system [51]. It may run health and accuracy check of any machine
component or subsystem. Daily QA is one module of TQA for daily routine checks of the machine. In particular,
it measures daily the leaf latencies (§ 1.1.1).
For routine TPS QA, Accuray provides the synthetic “TomoPhant” plans. Point dose measurements are per-
formed with ionisation chambers in the Cheese Phantom in gradient and flat dose regions. There is a TomoPhant
plan for each delivery mode (helical or topographic) and each jaw mode (static or dynamic). The plans have two
off-axis cylindrical targets of 6 cm.
The original patient-specific DQA recommended by Accuray was to measure a two-dimensionnal (2D) dose
distribution with a radiochromic film and an absolute point dose with an ionisation chamber in the Cheese Phantom.
At least four commercial systems have been validated to replace the film measurements. They use a diodes or
ionisation chambers array placed in a phantom. Amongst the validated systems, one may find Octavius (PTW,
Freiburg, Germany) [52], Delta4 (ScandiDos, Uppsala, Sweden) [53], MapCHECK (Sun Nuclear, Melbourne FL,
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USA) [54], and ArcCHECK (Sun Nuclear, Melbourne FL, USA) [55].
The first in vivo dosimetry attempts in tomotherapy were conducted by Kron et al. [56]. They placed dosimetric
films on the treatment couch under the patient. Qi et al. [57] used MOSFET detectors during the treatment of
naso-pharyngeal carcinomas. They used moulded oral plates to position the MOSFET dosimeters and measured
in vivo the dose to the patient’s tongue. Alnaghy et al. [58] measured in vivo the dose to the anterior rectal wall
using MOSFET dosimeters during prostate boost treatments.
Three groups proposed dose reconstruction algorithms for tomotherapy [59–63]. There exists also a commercial
in vivo and pretreatment DQA dosimetry software, Dosimetry Check (Math Resolutions, Columbia MD, USA),
which was recently bought and incorporated into RadCalc (LAP, Lu¨neburg, Germany). It uses either the primary
fluence or the exit fluence (if a phantom or a patient is on the treatment couch) measured by the OBD (§ 1.1.4)
to reconstruct three-dimensionnal (3D) dose distributions in the phantom’s or patient’s CT images. It relies on a
pencil beam collapsed cone convolution algorithm. Some authors reported to have implemented clinically RadCalc
on tomotherapy at their satisfaction [64, 65]. Mezzenga et al. [64] reconstructed “in vivo” the dose from the exit
fluence of three plans on the Cheese Phantom. They placed ionisation chambers in the target regions and reported
a mean dose deviation between the ionisation chamber measurements and RadCalc calculation of −1.4 %± 1.6 %.
1.4 Research introduction and motivation
In vivo dosimetry is still not widely spread in tomotherapy. The common patient-specific DQA consists in dose
measurements in a water equivalent phantom, implying tedious repetition of DQA measurements and absence of
patient-specific QA on the TPS side.
In the context of this thesis, the upgrade of an independent dose calculation software was developed and validated
(§ 1.4.1). In addition, to set the basis of an automated DQA tool, an algorithm was developed to measure on-line
the LOTs (§ 1.4.2) and was used to forward calculate the dose distribution in the patient’s CT images (§ 1.4.3).
This work aims to eventually alleviate the load of patient-specific DQA for medical physicists and to propose a
more dose-oriented acceptance criterion of the treatment plans.
To ensure the accurate delivery of the dose, one must ensure the accuracy of:
 the accelerator output,
 the patient’s position relatively to the radiation source,
 the jaw collimator and MLC operation.
The parameters of a majority of the machine components are logged by the DAS (§ 1.1.5). Amongst others, the
DAS data contain the monitor chambers reading, the couch position, and the gantry angle. During the treatment
delivery, these values are logged at each LINAC pulse, i.e. at a frequency of 300 Hz.
The dose output is controlled by a servomechanism. Thanks to that, Moutrie et al. [66] reported a stable
dose output both intrafractions and interfractions. The intrafraction output standard deviation was of 0.1 %.
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Concerning the couch position and the gantry angle, Handsfield et al. [67] reported that the values logged by the
DAS agreed with what was expected from the treatment plan. Neither did they report any quantified error, nor
did they specify whether they had applied particular tolerances. Though, couch position and gantry angle are
measured with uncertainties of 0.1 mm and 0.1°, respectively.
The jaw positions and the states of the MLC leaves (open, close, or switching) are not logged by the DAS.
Though, Lee et al. [68] verified the accuracy of jaw motion and position during nine months. They monitored the
jaw encoder error during a procedure with sweeping jaws, reporting a maximum error of 0.4 mm (in projection in
the isocentre plane). In the opposite, many authors have reported dosimetric errors related to the MLC inaccuracy
[63, 67, 69–71]. The pitch was identified as the problematic planning parameter. Pitches of 0.215 and smaller,
i.e. N > 4 (§ 1.1.3), caused significant mean relative LOT discrepancies [69, 72]. The tighter the pitch, the more
the beam overlaps with itself between successive rotations. Thus, the smaller the mean LOT required to deliver a
specific dose and the higher the relative LOT inaccuracy.
In summary, during normal operation of the machine, all components are reliable and operate with the desired
accuracy, except the MLC. Therefore, the work presented in sections 1.4.2 and 1.4.3 focuses on the effect of the
MLC inaccuracies on the delivered dose. Obviously, no QA check but DQA measurements can detect significant
LOT discrepancy. In section 1.4.3, a method to detect such errors either in air for pretreatment DQA or in vivo
is presented. The method relies on the detector raw data (§ 1.1.4) and could thus be fully automated. This is
very interesting, principally for two reasons. Firstly, as Ford et al. [22] calculated, the pretreatment DQA catches
only 1.4 % of severe potential errors. From this perspective, there is a strong interest in rationalising the efforts
nowadays put into manually performing pretreatment DQA checks. Secondly, as Arnold [21] pointed out, incidents
usually result from systematic failures. In that sense, it is interesting to have tools that could systematically
capture errors, before and while the dose is delivered.
1.4.1 Independent dose calculation
Thomas et al. [73] developed in MATLAB (MathWorks Inc, Natick MA, USA) an independent dose calculation
software for tomotherapy and called it CheckTomo. The software reads in patient’s CT images and treatment plans
from DICOM-RT files exported from the TPS. It allows the dose to be calculated at several points on a regular
3D grid. Gibbons et al. [74] had previously proposed an independent dose calculation software, but the calculation
was limited to a single point.
The calculation model of CheckTomo is based on empirical factors measured in fixed source skin distance (SSD)
condition, namely dose rate, field output factors, beam intensity profiles at different depths, and percentage depth
dose (PDD). The dose calculation is patient-specific. The software calculates the water equivalent depth (the
radiological path length) of the grid points with respect to the beam incidence angles and the electronic density
along the beam path. The software was originally released before the dynamic jaw mode of tomotherapy. Therefore,
CheckTomo did not offer the possibility to calculate the dose of dynamic jaw plans.
In the context of this thesis, it was investigated whether CheckTomo could be upgraded to calculate the dose
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of dynamic jaw plans. A method was eventually developed and specific tests were performed. This work has been
reported in article A, published in 2017.
CheckTomo algorithm models only longitudinally on-axis beams with longitudinally symmetric intensity profiles.
Yet, the very purpose of tomotherapy’s dynamic jaw mode is to produce off-axis beams. Additionally, it turns out
that these beams have longitudinally asymmetric intensity profiles. The main development challenge was thus to
reach an acceptable symmetric approximation of the profiles of the off-axis beams. The off-axis beam profiles were
measured at field widths of 10, 18, and 25 mm. A symmetric curve was fit on each profile (article A, figure 2).
(The off-axis beam profiles at other field widths are calculated on the fly by spline interpolation.)
The dose calculation accuracy of the dynamic jaw plans was evaluated on 5 simple synthetic plans and on 30
real clinical plans that had been approved for treatment. First, the dose of dynamic jaw TomoPhant plans (§ 1.3)
with various PTV lengths was calculated. The error between CheckTomo and TPS longitudinal dose profiles was
calculated. Then, the dose of clinical dynamic jaw treatment plans was calculated. There were 10 abdomen, 10
head and neck (H&N), and 10 breast plans. CheckTomo and TPS dose distributions were compared with γ-index
pass rates (§ 1.2.2). Various DD (global normalisation) and DTA tolerances were used. To calculate the pass rates,
the minimum dose threshold was fixed at 50 % of the dose maximum (i.e. points below the 50 % isodose level were
excluded from the pass rate calculations). Finally, some errors were simulated on the treatment plans that had
had a pass rate above 95 % for tolerances of 3 %/2 mm. It was checked whether these errors could be detected by
a γ-index pass rate test with tolerances of 3 %/ 2 mm and a pass rate threshold of 95 %.
1.4.2 On-line leaf open time measurement
As mentioned in the introduction of this section, there is a strong interest in measuring the actual LOTs to calculate
more accurately the delivered dose. An algorithm to measure the LOTs from the OBD pulse-by-pulse data was
developed. It was extensively presented in article B.
The OBD is active during the treatment dose delivery and collects the fluence exiting the patient (§ 1.1.4). It
was possible to map each leaf to a specific detector channel. Then, determining the leaf state consisted in observing
the signal in the leaf’s channel. The period of time during which the leaf is open corresponds to a peak in the
detector signal. The related LOT was defined as the peak’s full width at half maximum (FWHM).
The principal difficulty was to ensure the algorithm accuracy without having the opportunity to rely on an
external reference. The state of the MLC leaves is checked on-line by optical sensors [8], but the sensors output is
not logged by the DAS. As a workaround, the LOTs measured by the algorithm were checked step-by-step, starting
in simple conditions and adding complexity layers:
1. The LOT errors were compared to those reported by the Daily QA module of TQA. This meant measuring
the LOTs without attenuation material in the beam path and under static jaws.
2. The effect of the field width on the LOT measurement was investigated in air on dynamic jaw procedures.
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3. On the same dynamic jaw procedures, the effect of the beam attenuation by the patient on the measured
LOTs was investigated.
1.4.3 Delivered dose accuracy investigation through forward calculation
The aim of the work presented in article C was to propose and to validate clinically a DQA method with a dose-
oriented approach. In particular, it was investigated whether the LOT discrepancies related to the dose in the
PTV, with the idea to propose an indicator of the dose delivery quality based on the measured LOTs.
The principle is to measure the LOTs with the algorithm presented in article B and to calculate the dose
actually delivered by replacing the planned LOTs with the measured LOTs in the treatment plan. In this work,
the calculations were performed with Accuray’s standalone dose calculator [75].
It was first tested whether the method would successfully highlight LOT discrepancies and accurately calculate
the delivered dose in synthetic conditions. Six plans with intentional random LOT errors were generated from
the TomoPhant plan with a dynamic jaw field of 2.5 cm. The random errors followed Gaussian distributions with
means of −6 %, −4 %, −2 %, 2 %, 4 %, and 6 %, respectively. Each modified plan was delivered. The dose was
measured with two ionisation chambers, one at the centroid of each of the TomoPhant plan targets. The OBD raw
data were collected and the LOTs subsequently calculated. The delivered dose was calculated using the measured
LOTs and compared to the dose measured with the ionisation chambers.
60 clinical treatment plans were selected randomly, 30 on each of CHUV’s treatment unit. The plans were
delivered in air with the couch retracted out of the bore (static couch DQA procedures). For each plan, the delivered
dose was calculated using the measured LOTs. The correlation between the mean relative LOT discrepancy and
the change of the dose covering 95 % of the PTV (D95) was calculated. The plans pitch were of 0.287 or 0.215
(N = 3 or N = 4, c.f. § 1.1.3). 0.215 is a value known to cause significant mean relative LOT discrepancies (§ 1.4).
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Chapter 2
Overview of the results
In this chapter, we briefly summarise the results of the three scientific articles in the appendix.
2.1 Independent dose calculation
First, the dose calculation accuracy of CheckTomo on plans with dynamic jaws is reported. The calculation
accuracy was evaluated on TomoPhant synthetic plans and on clinical plans. Then, the sensitivity of CheckTomo
to simulated errors is reported.
The error committed when symmetrically modelling the off-axis beam asymmetrical intensity profiles was
estimated. Measured (asymmetrical) and fitted (symmetrical) beam profiles are represented in figure 2 of article A.
The maximum error, relatively to the on-axis beam output, was below 3 %. It is not obvious how this relates to
the inaccuracy of the calculated dose.
It was more interesting to investigate whether CheckTomo calculated accurately the dose in synthetic conditions,
i.e. on dynamic jaw TomoPhant plans. The results are reported in figure 4 of article A and reproduced here with
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Figure 2.1 – Longitudinal dose profiles of the dynamic jaw TomoPhant plans for two PTV lengths, computed by the
TPS (plain lines) and CheckTomo (dots), with the relative calculation error of CheckTomo (dashed lines). In this case, the
relative jaw penumbral filter were sampled at 10, 18, and 25 mm.
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additionally the relative error (figure 2.1). The error was normalised by the planned dose at the centre of the profile
(2.01 Gy). On plans with a field width of 2.5 cm, the dose error ranged from −3.2 % to 2.4 %. With a field width
of 5.0 cm, it increased to a range from −11.1 % to 2.9 %. The largest errors were at the edges of the dose plateau.
CheckTomo and TPS dose distributions were compared on 10 abdomen, 10 H&N, and 10 breast plans with
γ-index pass rates (article A tables 2, 3, and 4, respectively). The DD (global normalisation) tolerance had the
most influence on the pass rates. Plans in the abdomen region were the most accurately calculated. In the opposite,
plans in the H&N region had the lowest pass rates.
The accuracy of the γ-index pass rate test was calculated (article A table 5). In this context, “accuracy” is the
ability of the test to detect correctly if plans are clinically acceptable or not. With tolerances of 3 %/ 2 mm and
a pass rate threshold of 95 %, the accuracy of the γ-index pass rate test was of 47 %. This means that the pass
rate of 53 % of the analysed clinical plans was below 95 %, even though all plans were clinically acceptable. The
accuracy was of 100 % with a DD tolerance of 6 %.
Finally, the pass rate (tolerances of 3 %/ 2 mm) of all plans felt below the 95 % threshold when either a dose
shift of 3 % or a spatial shift of 4 mm was applied (article A table 6).
2.2 On-line leaf open time measurement
First, the agreement between the LOTs measured by the algorithm and by TQA is reported. Then, the effects of
the field width and of the beam attenuation on the LOT measurement are reported.
The agreement between the LOTs measured by the algorithm and those measured by TQA was of 0.0± 0.3 ms
(one standard deviation).
The standard deviation and mean of the discrepancies between measured and planned LOTs did not depend
on the jaw aperture in dynamic J20 procedures (article B figure 5). Yet, the detector data were not exploitable at
the beginning and at the end of dynamic jaw J42 procedures, below a jaw aperture of 12.4 mm (article B table 2).
This is because the beam is off the source axis and the detector is in the beam umbra. Finally, the discrepancy
distributions were the same in air and in vivo (article B figure 6).
LOT discrepancies were measured up to 45 ms. These large values were related to either a short (below 30 ms)
or a large (within 30 ms of the projection time) planned LOT. Planned LOTs may range from 18 ms to the
projection time (§ 1.1.1).
2.3 Delivered dose accuracy investigation through forward calculation
First, the output of the measurements on the modified TomoPhant plans are reported. The discrepancies between
measured and planned LOTs were calculated. The dose agreement between ionisation chamber measurements and
calculations based on the measured LOTs was established. Then, correlations calculated between the mean relative
LOT discrepancy and the dose change in the PTV (D95) on two sets of 30 clinical plans are reported.
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On the modified TomoPhant plans, the intentional LOT discrepancies could be highlighted. On each of the
TomoPhant plans (one reference and six modified plans), the mean relative discrepancy between measured and
planned LOTs was of 1.10±0.05 % on TOMO1 and of 0.02±0.03 % on TOMO2 (N = 14, one standard deviation,
article C figures 2 and 3).
The agreement between the dose calculated from the measured LOTs and the dose measured with ionisation
chambers in the Cheese Phantom on the TomoPhant plans was of 0.2 ± 0.3 % on TOMO1 and of 0.1 ± 0.3 % on
TOMO2 (N = 28, one standard deviation). The maximum difference was of 1 % (article C figure 4).
On the clinical plans, the correlation between the mean relative LOT discrepancy and the dose deviation in the
PTV was of 0.76 (p ≈ 10−15) on TOMO1 and 0.65 (p ≈ 10−10) on TOMO2 (article C figure 6). There was no such
correlation between the γ-index pass rate and the PTV dose (article C table 1 and figure 7).
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Chapter 3
Discussion
Independently calculating the planning dose tests the TPS algorithm in heterogeneous media. It constitutes a
patient-specific QA on the TPS side. Measuring on-line the machine parameters is a patient-specific DQA. In that
sense, the work presented in the article A and that presented in articles B and C are complementary, because
patient-specific DQA and TPS QA are complementary.
Admittedly, we were misunderstanding this when we wrote article A:
“Performing an independent dose calculation with CheckTomo is not as comprehensive as actually
measuring it during a QA procedure, in that sense that it performs no control on the machine side.”
(Article A, § 3.B.2, 98)
Measuring the dose in a water equivalent phantom is indeed a machine DQA, but the measured dose is compared
to a dose calculated in a homogeneous medium. In that sense, it lacks a true verification of the calculated dose
accuracy in the patient’s anatomical structures.
The extent and type of IMRT verifications to perform is an open topic. In particular, whether or not to base
the IMRT QA on softwares and/or machine logs have already been heavily debated [76, 77]. Here, the independent
dose calculation software CheckTomo relies on independently measured beam data and an independent algorithm.
The LOT measurement algorithm is based on machine logged raw values. The algorithm itself is independent.
3.1 Independent dose calculation
An upgrade of an existing independent dose calculation software for tomotherapy, CheckTomo, was implemented.
The upgraded was required to follow the TomoEDGE evolution of the tomotherapy system. Article A presented
upgrade implementation in the calculation model of CheckTomo and presented how the accuracy of the calculated
dose distributions was investigated.
The inaccuracy of the dose calculated on the synthetic TomoPhant plans was high, up to 11 % with a field width
of 5.0 cm (figure 2.1). This inaccuracy could be reduced by increasing the sampling of the off-axis beam profiles
(figure 3.1). The beam profiles were originally sampled at 10, 18, and 25 mm. Meanwhile, four samples have been
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Figure 3.1 – Longitudinal dose profiles of the 5 cm dynamic
jaw TomoPhant plans for two PTV lengths, computed by the
TPS (plain lines) and CheckTomo (dots), with the relative
calculation error of CheckTomo (dashed lines). In this case,
the relative jaw penumbral filter had been sampled at 10, 18,
25, 30, 35, 40, and 45 mm.
added at 30, 35, 40, and 45 mm. With this modification, the error committed when calculating the 5 cm dynamic
jaw TomoPhant plans ranged from −5.6 % to 3.1 % (previously from −11.1 % to 2.9 %). Yet, only 2 of the 30
clinical treatments analysed in article A were planned with a field width of 5.0 cm. Of those, only one (article A
table 2, plan A06) had low γ-pass rates. Thus, the sampling modification introduced here would not change the
overall results and conclusions of article A. Anyway, a calculation error greater than 5 % in simple conditions like
the TomoPhant plan is not satisfactory.
Thomas et al. [73] reported mean γ-index pass rates (3 %/3 mm) of 96.3 % and 89.2 % on prostate and H&N
static jaw plans, respectively. In article A, mean pass rates (3 %/3 mm) of 95.9 % and 90.3 % were reported
on abdomen and H&N dynamic jaw plans, respectively. This indicates that the software calculates the dose as
accurately on static jaw plans as on dynamic jaw plans. In that sense, the upgrade was successful.
The γ-index pass rate test with tolerances of 3 %/2 mm and a threshold of 95 % detected all the errors simulated
by applying a global dose shift of 3 % or position shift of 4 mm. This means that CheckTomo had a high sensitivity
towards global errors. Though, regarding the high dose inaccuracy near the dose plateau on the TomoPhant plans
(figure 3.1), the sensitivity to errors of other types should be investigated (e.g. cold spots [78]).
Which is more, with tolerances of 3 %/2 mm, the software had a low overall accuracy. Only 47 % of the plans
passed the γ-index test. As there are no measurement or positioning uncertainty when comparing two calculated
dose distributions, tolerances of 3 %/2 mm seems reasonable. Thus, CheckTomo would yield too many false alarms
to be a reliable, useful QA tool.
Karlsson et al. [79] claimed in ESTRO booklet 10 that an independent dose calculation is a useful QA procedure
if an advanced algorithm is used. The question is to define what “advanced” means in this context. The booklet
recommends to use kernel-based models. CheckTomo relies on a empirical factor model measured in a water tank,
so not on an “advanced” algorithm in the recommendations’ sense.
The results reported and discussed here support ESTRO recommendations. In practice, CheckTomo should be
(and will likely be) superseded by more advanced algorithms.
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3.2 On-line leaf open time measurement
An on-line LOT measurement algorithm was developed. The results showed that the LOTs could be measured for
the various jaw and field width settings, except at the beginning and at the end of dynamic J42 procedures. In this
situation, the LOTs could not be measured at jaw apertures narrower than 12.4 mm. The results also showed that
the LOTs could be measured in air during a DQA procedure or in vivo with the patient on the treatment couch
during the delivery of a dose fraction. The main issue was to ensure the accuracy of the measured LOTs without
having the possibility to compare them to an external reference.
To test the algorithm, the measurement conditions went from simplest to most complex. First, the LOTs were
measured in air with static jaws, then in air with dynamic jaws, and finally in vivo with dynamic jaws. The
LOTs measured by the algorithm agreed closely to the LOTs measured by TQA. This indicates a low measurement
uncertainty in simple conditions. Then, successively adding complexity to the measurement conditions did not
impede the LOT measurements, i.e. the measurement uncertainty did not increase. In particular, in air and in
vivo discrepancy distributions had the same means and standard deviations (article B figure 6).
As mentioned, the LOT errors measured on Daily QA raw data agreed very well with those reported by
TQA. Thus, if the LOTs measured by TQA are accurate, those measured by the algorithm are also accurate.
As complexifying the measurement conditions did not impede the LOT measurement, the LOTs should be as
accurately measured in the simplest setting as in the more complex ones.
As mentioned in section 1.3, the machine daily checks are performed with the Daily QA module of TQA. During
the checks, the leaf opens 8 by 8 during 50, 100, 150, and 200 ms. This pattern is repeated twice, once at a jaw
opening of 7 mm and once at 20 mm. Thus, the LOT error measured for a specific leaf on a specific day is the
average of only two values. This should neither have artificially masked the actual, intrinsic LOT variability, nor
the uncertainty of the measured LOTs. In other words, measured LOTs were compared to other measured LOTs,
not means of repeated measurements to means of repeated measurements.
Additionally, Chen et al. [72] used a similar algorithm to measure the LOTs in air and in vivo. They had the
opportunity to compare the output of their algorithm to the optical sensors of the MLC controller on static jaw
plans. (TomoEDGE had not been released at that time.) Thus, their algorithm was validated against an external
reference on static jaw data. The algorithm presented here parses data of static jaw procedures very similarly
to that of Chen et al. [72]. Both algorithms should yield the same LOTs on static jaw data. Therefore, if one
algorithm measured reliably the LOTs of static jaw procedures, the other must have done as well.
One last problem must be addressed: the lack of consensus regarding the very definition of the LOT in to-
motherapy. In article B, the LOT was defined as the FWHM of the open leaf signal regions (article B, § II.B.3).
Taking the signal FWHM, i.e. choosing τOC = 0.5, was arbitrary. When looking at the detector signal, it is obvious
when a leaf is either fully closed or fully open. Though, there is no unique way of handling the signal gradients
(corresponding to the leaf switching between either states).
Amongst the other authors who also measured the LOTs form the OBD pulse-by-pulse data, Chen et al. [72]
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Figure 3.2 – Normalised signal under leaf 26 at projec-
tion 69 measured in vivo during a mediastinal treatment on
TOMO2 (article B table 1, patient 1). The measured leaf
open time (LOT) is given at different values of the open-close
threshold τOC (article B, § II.B.3).
also took the signal FWHM. Proceeding differently, Sevillano et al. [11] calculated an estimate of the normalised
primary leaf fluence from the OBD raw signal. They defined the LOT as the integral over time of the primary
fluence. In the context of article B, this would roughly consist in taking the integral over time of the deconvolved
and normalised OBD signal (article B, § II.B.2). Note that this would not work as such in vivo.
To estimate how the choice of the threshold τOC influences the LOT measurement, the LOT in an example case
was measured with different values of τOC (figure 3.2). Lowering or raising τOC by 0.2 yielded LOT variations of
2 ms. Therefore, the measurement inaccuracy must range from −2 to 2 ms.
In summary, the LOT measurement was impeded neither by the jaw aperture, nor by the beam attenuation. Yet,
the relation between the LOT and the leaf position has never been formally defined. It is not clear if a leaf should
be considered open once it has moved half way through the beam, or when it starts moving, or when it is finished
moving, etc. To choose the optimal threshold, the measured LOTs must be related to the measurable quantity
they control: the photon fluence. The first half of article C concentrated on assessing whether the measured LOTs
led to accurate dose calculation.
3.3 Delivered dose accuracy investigation through forward calculation
The work presented in article C brought back to the clinic the LOT measurement algorithm presented in article B.
An indirect validation of the measured LOTs accuracy through dose measurements and calculations in synthetic
TomoPhant plans was provided. The correlation between the relative LOT discrepancy and the dose change in the
PTV was investigated, allowing a LOT-based indicator of the dose delivery quality to be proposed.
On the synthetic TomoPhant plans, the measurements supported the feasibility of detecting LOT errors from
the OBD pulse-by-pulse data (article C figure 3). Figure 3 of article C shows the mean agreement between measured
and planned LOTs for all TomoPhant plans. On TOMO1, the measured LOTs were in average 1 % greater than
expected. This phenomenon did not happen on TOMO2. The mean LOT accuracy was of 2.0±0.1 ms on TOMO1
and of 0.1 ± 0.1 ms on TOMO2. (Note that this tells nothing about the measurement accuracy itself.) No leaf
latency correction was applied to the TomoPhant plans (§ 1.1.1). Interestingly, the latency correction that is
normally applied to clinical plans is of 2.4 ms on TOMO1 and 0.5 ms on TOMO2. If the latency correction had
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been applied to the TomoPhant plans, the mean LOT accuracy would be within 0.4 ms on both units. The aim
of measuring the LOTs on synthetic TomoPhant plans was to assess whether the measured LOTs allowed the
delivered dose to be accurately calculated. The aim was not to measure the accuracy of the leaf latency correction.
The intentional discrepancies introduced on the TomoPhant plans were chosen to be Gaussian because most of
the LOT error distributions reported in article B were bell-shaped (article B figure 6). Thus, the simulated errors
were comparable to the real LOT errors caused by the intrinsic MLC inaccuracy. Gross errors, like a leaf being
stuck open or closed, were not tested. They should not occur in the first place because the leaf controller would
interrupt the treatment in such situations. This work concentrated on testing uncaptured, yet clinically relevant
discrepancies.
Using the measured LOTs as input for the dose calculation led to an accurate prediction of the delivered dose.
The agreement between the ionisation chambers and the calculated dose was high (0.2 ± 0.3 % on TOMO1 and
0.1± 0.3 % on TOMO2, article C figure 4). In the TomoPhant plans used in the study, a mean LOT difference of
2 ms would lead to a dose difference of 1 %. This indicates that the choice of the threshold τOC within the LOT
measurement algorithm, as discussed in section 3.2, is appropriate.
With correlations of 0.76 (TOMO1) and 0.65 (TOMO2), the mean relative LOT discrepancy was a good
indicator of the dose deviation in the PTV (article C figure 6). This result differ from the previous findings of
Deshpande et al. [71]. They reported a steeper relation between mean LOT error and the dose change in the PTV.
One would expect the relation between fluence and LOT to be linear. Thus, the relation reported here (figure 3.4)
seems to make more sense. Additionally, Deshpande et al. [71] used a different LOT measurement algorithm.
They validated it by comparing the dose measured with ionisation chambers to the dose calculated based on the
measured LOTs (Deshpande et al. [71] table 3). They reported higher differences between measured and calculated
dose than what is reported in article C (article C figure 4), indicating that their LOT measurement algorithm has
room for finer calibration.
Observing the relation between the mean LOT discrepancy and the dose deviation in the PTV came from the
assumption that the LOT discrepancy distributions are symmetric. Figure 3.3 shows the dispersion of the relative
LOT discrepancy as a function of the planned LOT on thorax treatment plan. The LOTs were measured during
a static couch DQA procedure. Figure 3.3 also shows the planned LOTs and the LOT discrepancies histograms.
The LOT discrepancy distribution was not symmetrical in this case. The distribution had a secondary peak near
7 %. Thus discrepancies mean and median were not equal. On this plan, the difference was low (0.5 %). It was
higher (up to 2 %) in other of the clinical plans analysed in article C. As it turned out, the median (figure 3.4) was
a better predictor than the mean (article C figure 6) of the dose deviation in the PTV. The correlation between
median LOT discrepancy and dose deviation in the PTV was of 0.86 (p ≈ 10−23) on both plan sets.
Figure 3.4 show that the median relative LOT discrepancy is a good indicator of the dose delivery quality.
Yet, a plan evaluation cannot be limited to observing a single value. Therefore, the spatial dose difference was
also investigated in the plan that showed the greatest PTV dose deviation (figure 3.5). It appears that the dose
difference was not homogeneous over the whole target volume. In particular, the difference is above 3 % close to
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Figure 3.3 – Planned leaf open times (LOTs) and LOT discrepancy of thorax lesion treatment plan on TOMO2. The LOTs
were measured during a static couch DQA procedure. The horizontal lines in the LOT discrepancies histogram represent
the distribution mean (plain) and median (dashed).
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Figure 3.5 – Calculated delivered dose distribution and relative difference between planned and delivered dose of a thorax
lesion treatment plan on TOMO2. The related leaf open time (LOT) discrepancy distribution is represented in figure 3.3.
The median relative LOT discrepancy was of 1.5 % and the dose deviation in the ptv (D95) was of 2.4 % (figure 3.4).
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the heart. Consequentely, the dose deviation in the OARs was verified through DVH calculation and verification
(figure 3.6). The maximum dose to the heart and to the left lung increased by 0.5 and 1.3 Gy, respectively. The
median dose in the same OARs increased by 0.0 and 0.4 Gy, respectively. In an H&N plan, the dose difference
distribution allowed us to see hotspots along the carotid arteries (figure 3.7). Delivered dose DVHs and 3D dose
difference distribution will provide valuable information for the clinical evaluation of the treatment plans.
To fully validate the use the LOT measurement algorithm in conjunction with a standalone calculator, finer
measurements should be performed. Here, the accuracy of the measured LOTs was assessed by comparing calculated
and measured dose. The measurements were performed on the Cheese Phantom for synthetic TomoPhant plans.
Though, the TomoPhant plans do not require complicated LOT modulation patterns. The TPS is required to
cover PTVs with a single dose level (2 Gy) and is not required to protect any OAR. Comparing the calculated
dose of clinical plans (as the dose distribution shown in figure 3.5) to measurements (e.g. with films in the Cheese
Phantom) would be a finer validation.
Finally, the forward calculation based on the measured LOTs is not a comprehensive in vivo DQA tool. Firstly,
even though the LOTs can be measured with the patient on the treatment couch, the patient anatomy at the day
of the treatment is not taken into account. A first step would be to recalculate the dose in the patient’s daily
images. Though, the field of view (FOV) of the tomotherapy MVCT scanner is of 40 cm. In many situations, the
patient is partly out of FOV. Secondly, the independence of the standalone calculator versus the TPS algorithm
should be ensured. Alternatively, any robust independent dose calculation algorithm could be used.
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Chapter 4
Conclusion and perspectives
In the context of this thesis, a independent dose calculation algorithm was upgraded to keep up with the To-
moEDGE evolution of the tomotherapy treatment system. The results indicate that the upgrade was acceptable
in the sense that the software had the same overall accuracy on static jaw plans (which did not require the up-
grade) and on dynamic jaw plans (which did require the upgrade). Though, the overall software accuracy was low.
This questioned the software’s usefulness as QA tool. On the other hand, an on-line LOT measurement algorithm
was developed. The algorithm proved to be robust against the beam attenuation, thus allowing the LOTs to be
measured in vivo. The accuracy of the measured LOTs was assessed from dose measurements. The dose calculated
with the measured LOTs as input agreed very well with ionisation chamber measurements. Finally, measuring the
LOTs allowed dose deviations to be highlighted. The median (or the mean) relative LOT discrepancy showed a
correlation with the dose deviation in the PTV. Thus, the median discrepancy could serve as an indicator of the
dose delivery quality that has the advantage to be easy to measure.
Performing LOT-based DQA could help lighten the workload caused by the common IMRT DQA protocols.
As already mentioned, these protocols consist in measuring a dose fraction in a phantom for each patient. A
LOT-based method would only require the fluence to be delivered in air (with or without treatment couch in the
gantry bore). Moreover, the subsequent dose calculation in the patient’s planning CT images would provide more
valuable information than a dose difference measured in a phantom and evaluated with the γ-index metric. The
calculation of the delivered dose in the patient’s images allow the dose deviations to be evaluated directly over the
patient’s anatomy, thus revealing immediately the severity (or insignificance) of hot and cold spots. Finally, the
delivered dose can be evaluated through DVH calculation, making the severity of the overall difference between
planned and delivered dose directly assessable.
As the LOT measurement algorithm works in vivo, the LOT-based DQA could be automatically performed
at each treatment fraction. This would be a clear improvement compared to the current practice. Nowadays, no
DQA of each individual dose fraction is performed. The patient-specific QA merely stops at the pretreatment step.
From that point, the machine reliability is fully assumed. For the sake of completeness, and other perspectives
detailed hereafter, the opportunity to cheaply perform a DQA of each dose fraction is highly desirable. The LOT
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measurement algorithm presented here offers this possibility.
The LOT measurement algorithm could also make the patient flow more flexible by dropping pretreatment DQA
measurements. Of course, an in-depth risk analysis must precede such a decision. Some insights were provided
here. Firstly, the tomotherapy system has all the necessary interlocks to prevent severe accidents. Secondly, the
LOTs are the only parameters adjusted by the TPS on which the tolerance is high enough to cause clinically
relevant dose discrepancies. Other authors have reported it. In other words, accidents on a tomotherapy system
originating from hardware defaults are highly improbable thanks to the builtin interlocks, but PTV underdosage
has a non-negligible probability of occurrence. Though, it has been shown that large LOT errors originate from
requesting an over-tight pitch during planification. This fact sustains the recommendations of Huq et al. [23] to
place the QA checks in a broader framework and to insist on the staff training. The staff should be aware of the
possible “traps” of the system.
If the patient-specific QA is placed in the correct framework and if there is a possibility to perform in vivo
DQA of each dose fraction, then it seems reasonable to drop pretreatment DQA measurements for those planning
parameters known to not cause dose discrepancies. The dose discrepancies measured on the data collected for
artice C were in an acceptable ±2 % range (figure 3.4). This indicates that a correctly trained and experienced
staff produces clinically acceptable plans. Let us finally remark that, would an error happen, the in vivo DQA
would highlight it. As it is possible to calculate the delivered dose from the measured LOTs, it would be possible
to quantify the dose discrepancy, and it would thus be possible to adapt the following dose fractions to correct for
the original error. This, of course, is no primary option. It makes more sense to let no error occur in the first place,
because replanning would be more costly and more inaccurate than performing a pretreatment DQA measurement.
In addition, some indicators could help the staff decide whether or not they should perform a pretreatment DQA.
In particular, the mean planned LOT correlates with the pitch. The tighter the pitch, the lower the mean planned
LOT. Thus, the mean planned LOT (inversely) relates to the probability of delivering an inaccurate dose.
Combining the LOT measurement algorithm with an independent dose calculation algorithm would gather
together the TPS QA and the dose DQA. To constitute a fully comprehensive in vivo dosimetry method, the
combined LOT measurement and independent dose calculation approach should incorporate the patient’s daily
images. The delivered dose would be more accurately calculated on the patient’s daily images than on the planning
images. This should be made possible in a near future. Accuray recently added a fan-beam CT scanner to its
tomotherapy system.
Then, it would presumably be possible to observe the drift of the dose error as the patient’s anatomy changes
(weight loss, tumour size reduction, etc.). The delivered dose could be summed over the treatment fractions, thus
allowing the clinicians to calculate more accurate adaptive treatment plans.
Another extension of an in vivo DQA method would be to check the patient position during the treatment, e.g.
by reconstructing images during the delivery from the treatment beam or by identifying the patient’s contour. It
would go even further by merging a patient position verification with a tumour tracking feature and a respiration
correlated dose accumulation algorithm.
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Finally, the LOT measurement algorithm could also be used for machine QA purpose. The medium term (over
several months) drift of the LOT inaccuracies could be monitored and related to MLC breakdowns. As for now,
TQA monitors the maximum daily LOT inaccuracy. Accuray recommends preventive servicing when the maximum
error is greater than 20 ms. This does not fully prevent MLC breakdowns, so either the tolerance is too low or the
monitored value is inadequate. The per leaf drift of the LOT inaccuracy could be measured in real usage conditions
thanks to the ability of the algorithm to measure the LOTs in vivo. In contrast, TQA measures the LOTs in very
synthetic conditions during the daily checks of the units. The inaccuracy drift could be an indicator of the MLC
degradation. A predictor of MLC breakdowns would be of high interest. It could help reducing the machine down
time by preventively servicing or replacing the MLC.
The work done and published in the context of this thesis is a valuable basis for the development of handy
and more accurate DQA and machine QA tools for tomotherapy. It offers the opportunity to automatise patient-
specific DQA, thus to reduce the considerable, human resources put into systematic performing pretreatment DQA
in tomotherapy. Within a comprehensive QA framework and in parallel with exhaustive knowledge of the treatment
system, it offers the opportunity to make the DQA practice in tomotherapy more flexible, namely by dropping
pretreatment measurements in most situations. Finally, it offers the opportunity to monitor the delivery of each
dose fraction individually, without demanding more efforts from the staff. This is an obvious improvement with
respect to the current practice.
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Abstract
Purpose: CheckTomo is an independent dose calculation software for tomotherapy.
Recently, Accuray (Accuray Inc., Sunnyvale, CA, USA) released an upgrade of its
tomotherapy treatment device, called TomoEDGE Dynamic Jaws, which improves
the quality of treatment plans by enhancing the dose delivery with the help of jaws
motion. This study describes the upgrade of CheckTomo to that new feature.
Methods: To account for the varying width and off-axis shift of dynamic jaws fields,
the calculation engine of CheckTomo multiplies the treatment field profile by a
penumbral filter and shifts the dose calculation grid. Penumbral filters were obtained
by dividing the edge field profiles by that of the corresponding nominal field. They
were sampled at widths 1.0, 1.8, and 2.5 cm at isocenter in the edges of the 2.5
and 5 cm treatment field.
Results: The upgrade of CheckTomo was tested on 30 patient treatments planned
with dynamic jaws. The gamma pass rate averaged over 10 abdomen plans was
95.9%, with tolerances of 3 mm/3%. For 10 head and neck plans, the mean pass
rate was 95.9% for tolerances of 4 mm/4%. Finally, misplacement and overdosage
errors were simulated. In each tested cases, the 2 mm/3% gamma pass rate fell
below 95% when a 4 mm shift or 3% dose difference was applied.
Conclusions: These results are equivalent to what CheckTomo achieves in static
jaws cases. So, in terms of dose calculation accuracy and errors detection, the
upgraded version of CheckTomo is as reliable for dynamic jaws plans as the former
release was for static cases.
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1 | INTRODUCTION
Independent dose verification is considered to be important to ensure
patient safety.1 It can be performed through an independent calcula-
tion with commercial softwares for three-dimensional conformal radia-
tion therapy (3DCRT), image-modulated radiation therapy (IMRT), and
volume-modulated arc therapy (VMAT) treatments. For tomotherapy,
as far as we know, there exists a commercial tool, Mobius 3D (Mobius
Medical Systems, Houston, TX, USA), and a single-point dose verifica-
tion software.2 Additionally, an open source solution, CheckTomo,
was released in 2011.3 That software independently generates a
three-dimensional point-based dose distribution, using patient CT
images and delivery plan, and compares it against the dose volume cal-
culated by the tomotherapy treatment planning system (TPS).
Accuray (Accuray Inc., Sunnyvale, CA, USA) released an upgrade
of its tomotherapy device called TomoEDGE Dynamic Jaws.4 The
purpose of this upgrade is to reduce the field penumbra along the
patient longitudinal (inferior–superior) axis by the mean of jaws
motion. The way the dose is delivered is hence modified and the
dose calculation engine of CheckTomo needed to be upgraded
consequently.
This study aims to present the work done to develop and imple-
ment the upgrade of CheckTomo and the tests that were performed
to assess that the dose calculation carried out with the upgrade is as
reliable as it was with the previous version. It does not suggest any
improvement of the core calculation engine.
2 | MATERIALS AND METHODS
2.A | TomoEDGE dynamic jaws
In tomotherapy, the field is delimited in the longitudinal (IEC-y)
direction by a pair of collimators, called jaws. A non-TomoEDGE
direct or helical tomotherapy treatment is delivered with static jaws,
i.e., at fixed field width during the whole treatment procedure, either
1, 2.5, or 5 cm at isocenter. This implies that the field penumbra in
the longitudinal direction is of approximately the field size on both
cranial and caudal sides of the target. To limit the extra dose to
organs at risk (OAR) and other healthy tissues, the treatment can be
delivered with a smaller field width, but this usually increases the
irradiation time.
To overcome this poor trade-off, TomoEDGE introduced jaws
motion during treatment delivery.5 At treatment start, the jaws deli-
mit at isocenter an asymmetrical 1 cm wide field, located off the
source axis toward the patient’s feet. Then as the couch moves for-
ward, the cranial jaw sweeps toward the patient’s head to keep the
field edge 5 mm ahead of the planning target volume (PTV), until the
jaws delimit a symmetrical field (respectively to the beam axis) of
the nominal treatment size, either 2.5 or 5 cm at isocenter. Similarly,
the caudal jaw closes behind the PTV as it exits the beam, until the
field is 1 cm wide again.4 In a TomoEDGE treatment, the penumbra
on the cranial and caudal sides of the PTV is reduced to 1 cm. See
Fig. 1 for a graphical depiction.
For clarity, the fields will be denominated “nominal” when delim-
ited by symmetrically positioned static jaws and “edge” otherwise.
2.B. | CheckTomo
2.B.1 | Software basics
CheckTomo is a software written in MATLAB (The MathWorks Inc.,
Natick, MA, USA) that computes a three-dimensional point-based
dose distribution using CT data and treatment plan on the patient
side and independently acquired beam data on the machine side.
Patient data are read from DICOM CT and RT-plan files where
beam geometry and patient position during treatment are described.
Beam data are provided with CheckTomo for each nominal treat-
ment field in text files with a homemade structure. They consist of a
reference dose point, tissue-phantom ratios (TPRs), output factors
(OFs), and off-axis ratios (OARs) measured for various field shapes.
The 5 9 40 cm2 field at isocenter was taken as the reference one
and the dose reference point was measured isocentrically at depth
10 cm. All machine data were independently acquired on a
tomotherapy unit using an ionization chamber at different depths in
a water tank.
CheckTomo dose distribution is usually calculated on a grid of
15 9 15 9 15 points, with a 1 to 1.5 cm spacing. Grid resolution
and size can be adapted if needed. For each sinogram projection (or
control point), the dose deposited at a particular location is the
F I G . 1 . Schematic representation of a TomoEDGE treatment beam at two moments. Dashed lines represent the nominal field width. Edge
fields (in red) are represented at treatment start (right) and end (left). At treatment start, the jaws delimit a 1 cm wide field on the negative
IEC-y side of the beam axis. During treatment (not represented), as the PTV moves forward, the cranial jaw opens to keep the superior field
edge ahead of the PTV superior limit. Then, the caudal jaw closes to keep the inferior field edge behind the PTV inferior limit. Finally, when
the treatment ends, the jaws delimit a 1 cm wide field again, but on the positive IEC-y side of the beam axis.
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product of the projection time, the dose rate, TPR, OF, and OAR.
The fluence is considered to arise from the mean angle of the pro-
jection arc, which, regarding the tomotherapy standard of defining
51 control points per gantry rotation, extends over 7.29°. To
increase the number of control points and thus improve the dose
calculation accuracy, CheckTomo offers the option to split each pro-
jection into multiple subprojections.6
CheckTomo dose distribution can be compared to that calculated
by the tomotherapy treatment planning system (TPS) by means of a
gamma7 or box comparison index.8 Required patient data, beam
data collection, dose calculation model, and comparison indices
were explained in more detail in the original release paper of
CheckTomo.3
2.B.2 | Beam profile model
In CheckTomo, the longitudinal profile of a nominal field is calculated
by multiplying the field OAR, the TPR, and the OF. CheckTomo han-
dles OARs expressed in angular distance respectively to the beam
source, instead of Cartesian coordinates. It follows the tomotherapy
naming conventions of field size, calling the longitudinal dimension
the width and the in-plane dimension the length (width and length
are always given at isocenter). Which is more, the OF of the
tomotherapy beam, hereafter Scp, is not a function of the equivalent
square field size but depends independently on both the field width
and length.3 In CheckTomo, it is therefore considered to be a func-
tion Scp;w0 of the field length specific to the nominal field of width
w0.
Thus, the longitudinal profile at angular coordinate hy and depth
d of a nominal field of width w0 and length L is given by
PNðw0; L; hy; dÞ ¼ OARyðhy; dÞ  TPRðAsq; dÞ  Scp;wo ðLÞ: (1)
Asq is the equivalent square field size.
2.C. | Implementation of a dynamic jaws beam
profile model in CheckTomo
Jaws motion induces changes in the field shape and OF that have to
be accounted for in the profile model. Theoretically, the longitudinal
profile of an edge field is obtained by multiplying Eq. (1) by a jaw
penumbral filter and by correcting the OF. But as mentioned in sec-
tion 2.B.2, the OF function Scp was not designed to account for a
varying field width. To overcome this limitation, the relative jaw
penumbral filter (RJPF) was introduced, defined as the ratio of the
edge and nominal longitudinal profiles PE and PN,
RJPFðw;w0; hy; dÞ ¼ PEðw;w0; L; hy; dÞPNðw0; L; hy; dÞ : (2)
Here PE is the edge field profile given in angular coordinates
respectively to the beam source. The transformation consists in first
applying a coordinates shift along the longitudinal axis so that the
field maximum is at IECy = 0. Then, the shifted Cartesian coordi-
nates are converted in angular distances.
The edge field profile equation is obtained by inverting rela-
tion (2) and replacing PN with equation (1), namely
PEðw;w0; L; hy; dÞ ¼ OARyðhy; dÞ  TPRðAsq;dÞ  Scp;w0 ðLÞ
 RJPFðw;w0; hy; dÞ:
(3)
Note that it yields a profile originating at the source axis. To
account for the edge field off-axis nature, the dose calculation grid is
shifted longitudinally — toward head or feet depending on the edge
side — by half the field width.
In practice, PE and PN were sampled at field widths and
depths specified in section 2.D, normalized, respectively, to PN
peak maxima and converted into angular coordinates. RJPFs were
then calculated from Eq. (2) by interpolating PE and PN over for a
set of arbitrary points. These data were stored in new text files
structured like the existing CheckTomo beam data files. Note that
the RJPFs were not sampled at different field lengths because it
was checked that this parameter only has a slight influence on
the longitudinal profiles. Lastly, for widths and depths falling
between sampling values, the RJPF is interpolated on the fly at
run time.
2.D. | Measurements of edge beam data
Profiles measurements were performed with an Exradin A1SL ioniza-
tion chamber (Standard Imaging, Middleton, WI, USA) in a water
tank at SSD 85 cm, all MLC leaves open and depths 1.5, 5, 10, 15,
and 20 cm. They were all run successively for the nominal and edge
fields.
Measurements of both the edge and nominal profiles were
needed to calculate the RJPF from Eq. (2). The edge field width
varying continuously between 1 cm and the nominal field size, it
was necessary to pick some sampling values. During the TomoEDGE
acceptance test procedure (ATP), field data were measured for
widths 1.0, 1.8, and 2.5 cm in both edges of 5 cm nominal field. We
decided to perform profile measurements for that same set of val-
ues. Due to the flattening filter free (FFF) beam of tomotherapy
units, the profile of an edge field depends also on its distance to the
source axis. So, similar measurements were performed in the edge of
the 2.5 cm nominal field as well. Obviously, it was sufficient to real-
ize them only on one side of the source axis.
2.E. | Dose calculation verification and tests of
accuracy
2.E.1 | Gradient check
Five plans were generated using the images of the Cheese Phantom
and the 5.0 cm plans structures set provided with the TomoPhant
IMRT verification patient, which is usually available in the tomother-
apy TPS. Three PTVs of 2 cm, 6 cm, and 10 cm were created by
shrinking or extending the original target volume. Plans were calcu-
lated for the 2.5 cm field on these three PTVs and for the 5 cm field
on the 6 cm and 10 cm PTVs. All plans were calculated in dynamic
jaw mode. The PTVs were centered on the machine isocenter, the
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prescription dose was of 2 Gy and the pitch was 0.287. To force
some field modulation, a constraint was applied on a structure of the
same size as the target located 2 cm beneath it.
All five plans were calculated in CheckTomo with a 2.5 mm lon-
gitudinal spacing and global 2 mm/3% and 3 mm/4% gamma indices
were calculated. Additionally, the dose profiles along the longitudinal
axis in the isocenter plane were extracted from both the CheckTomo
and tomotherapy TPS dose volume so that they could be compared
visually.
2.E.2 | Dose verification in real patient cases
The upgrade of CheckTomo was tested on 30 patient cases planned
and treated with dynamic jaws. All plans had successfully passed a
clinical quality assurance (QA) test which consisted in comparing the
TPS dose distribution to a measurement performed with an Octavius
729 detector array in an Octavius II phantom (PTW, Freiburg,
Germany). Dose comparison was done in VeriSoft (PTW, Freiburg,
Germany) using a 3 mm/3% gamma comparison index7 for points
within the 10% isodose and considering a 95% pass rate threshold.
The independent calculation of the dose distributions was per-
formed with the upgraded version of CheckTomo using the original
patients CT images, a 31 9 31 9 31 calculation grid with a longitu-
dinal spacing of 6 mm (8 mm in two cases) and one subprojection
per projection. These grid settings ensured us to cover in each case
a major part of the PTV and to get a reasonably high dose point res-
olution in the field edges. Note that in some cases, the PTV was too
large to fit entirely in the dose calculation grid. PTV length and field
width for each patient are given in Tables 2–4.
The calculation accuracy was assessed for each of the 30 plans
by computing the mean dose difference and performing global
gamma comparison tests between the CheckTomo and the
tomotherapy TPS dose distributions. The gamma index was calcu-
lated for various tolerances over the points located within the 50%
isodose and at least 5 mm deep in the patient’s body. A test is con-
sidered successful if its gamma pass rate is above 95%.
2.E.3 | Errors simulation
Finally, in order to test the ability of the upgrade of CheckTomo to
detect errors, 15 cases that had passed a 2 mm/3% gamma compar-
ison test were selected, independently of the treatment location.
Then longitudinal misplacements and overdosages were simulated
over them by applying a 2 mm and 4 mm coordinate shift and a 3%
dose offset to the TPS dose distribution.
3 | RESULTS AND DISCUSSION
3.1 | Edge beam data and profiles model
Figure 2 shows field profiles measured and calculated on the positive
IEC-y side of the gantry. All profiles were normalized to the maxi-
mum of the corresponding nominal field. The difference in relative
intensity between a profile in the edge of the 2.5 cm and 5 cm nom-
inal field is visible, particularly for the 1 cm field.
Note that Eq. (3) yields a symmetric approximation of the edge
field profiles, which are actually asymmetric (because the position of
the jaws compared to the axis of the beam generates asymmetric
penumbra). This approximation is inherent to the beam model of
CheckTomo, which was not designed to handle asymmetric fields.
Though, as can be seen in Fig. 2, the calculated edge profiles (plain
TAB L E 1 Gamma pass rate (c) for two tolerances and average
mean dose difference (DD) of the five plans calculated in the
TomoPhant. Points within the 50% isodose and at least 5 mm depth
were considered in the calculation of the gamma index.
Field
width [cm]
PTV
length [cm]
c 2 mm,
3% [%]
c 3 mm,
4% [%] DD [%]
2.5 2 91.2 96.4 2.2
2.5 6 100.0 100.0 0.0
2.5 10 99.8 100.0 1.0
5.0 6 88.0 96.0 0.1
5.0 10 86.7 95.3 0.9
TAB L E 2 Geometrical setup, gamma pass rate (c) for various tolerances and average mean dose difference (DD) of the 10 abdomen plans.
Points within the 50% isodose and at least 5 mm depth were considered in the calculation of the gamma index.
Case PTV dose [Gy] Field width [cm] PTV length [cm] c 2 mm, 3% [%] c 3 mm, 3% [%] c 4 mm, 4% [%] DD [%]
A01 2 5.054 30.2 97.8 99.2 100.0 0.9
A02 1.8 2.51 29.2 83.7 88.6 96.4 1.8
A03 2 2.51 9.75 100.0 100.0 100.0 0.27
A04 1.8 2.51 17.6 97.0 98.2 99.2 0.5
A05 7 2.51 3.8 97.5 99.1 100.0 1.93
A06 1.8 5.054 20.4 84.2 89.6 94.5 1.38
A07 2 2.51 13 99.5 99.8 100.0 0.2
A08 2 2.51 12.2 83.6 85.8 93.0 2.56
A09 3 2.51 19.2 97.9 98.6 99.7 0.8
A10 2.3 2.51 33.4 99.6 99.9 100.0 0.7
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lines) show a good agreement with the measurements (dots). The
maximal error induced by the approximation of Eq. (3) is of respec-
tively 2.7% and 1.5% for the 1 cm and 2.5 cm edge fields. Also note
that in Eq. (3), the spatial coordinate is the angular distance at the
source, but that the field profiles are represented in Fig. 2 in Carte-
sian coordinates.
Figure 3 shows the relative jaw penumbral filters of the 2.5 cm
and 5 cm nominal field, defined by Eq. (2) and calculated using the
measured profiles shown in Fig. 2. One can see that the RJPFs are
depth-dependent, as are the field profiles. Also, one should note
that they do not converge toward 0 when reaching the field limit,
as would be expected. This is a numerical artifact: obviously, both
the nominal and edge field profiles also tend toward 0 at the field
boundary, and dividing two small values one with another [in
Eq. (2)] may result in large numbers. In other words, the RFJPs are
hardly calculable outside the field. Though, this is not an issue
because the product of the profile and the RJPF [in Eq. (3)] con-
verges toward 0 at the field limit. As can be seen on Fig. 2, the
calculated edge field profiles (plain lines) match the measurements
(dotted lines).
Finally, CheckTomo upgrade was designed having in mind that
TomoEDGE could in the future evolve and perform more complex
dose sculpting. One can think of sharpening the edges of a simulta-
neous integrated boost (SIB) or tracking a tumor.
TAB L E 5 Number of successes to the gamma comparison test
(Nc>95%, i.e., pass rate above 95%) and mean gamma pass rate (c) for
various tolerances for the three different regions investigated. Ten
treatment plans were tested in each region. Points within the 50%
isodose and at least 5 mm depth were considered in the calculation
of the gamma index.
Abdomen and
pelvis Head and neck Breast
Nc>95% c [%] Nc>95% c [%] Nc>95% c [%]
2 mm, 3% 7 94.1 3 86.8 4 88.7
2 mm, 4% 7 97.2 7 93.1 5 92.3
3 mm, 3% 7 95.9 4 90.3 5 93.5
3 mm, 4% 8 97.9 7 95.0 8 94.9
3 mm, 5% 10 98.9 7 97.5 9 98.0
3 mm, 6% 10 99.4 10 98.5 10 98.9
4 mm, 4% 8 98.3 7 95.9 8 97.1
DD [%] 1.1 1.8 1.8
TAB L E 3 Geometrical setup, gamma pass rate (c) for various tolerances and average mean dose difference (DD) of the 10 head and neck
plans. Points within the 50% isodose and at least 5 mm depth were considered in the calculation of the gamma index.
Case PTV dose [Gy] Field width [cm] PTV length [cm] c 2 mm, 3% [%] c 3 mm, 3% [%] c 4 mm, 4% [%] DD [%]
HN01 2 2.51 12.75 69.2 74.6 88.9 3.7
HN02 2.12 2.51 7.75 65.6 76.6 89.6 3.1
HN03 2.12 2.51 14.75 100.0 100.0 100.0 0.3
HN04 2.12 2.51 15 88.1 91.8 97.9 2.3
HN05 2 2.51 12.4 90.0 92.5 97.5 2.2
HN06 2.12 2.51 15.6 93.5 96.1 98.5 1.6
HN07 2 2.51 13.8 92.3 93.3 96.8 0.9
HN08 2 2.51 11.2 75.0 82.0 90.6 3.0
HN09 2.12 2.51 16 95.2 96.7 99.0 0.8
HN10 2.12 2.51 18.75 99.2 99.3 100.0 0.1
TAB L E 4 Geometrical setup, gamma pass rate (c) for various tolerances and average mean dose difference (DD) of the 10 breast plans. Points
within the 50% isodose and at least 5 mm depth were considered in the calculation of the gamma index.
Case PTV dose [Gy] Field width [cm] PTV length [cm] c 2 mm, 3% [%] c 3 mm, 3% [%] c 4 mm, 4% [%] DD [%]
B01 2 2.51 23.6 91.5 95.2 98.2 2.0
B02 2 2.51 14.4 73.4 81.8 91.5 2.8
B03 2 2.51 21.8 87.4 92.6 96.8 2.0
B04 1.8 2.51 21.4 98.1 99.1 99.7 1.3
B05 2 2.51 25.4 95.8 97.0 99.7 1.5
B06 2 2.51 24.6 98.2 98.8 99.7 0.5
B07 2 2.51 20.6 90.2 93.7 97.8 2.0
B08 2 2.51 20.4 85.1 91.0 96.5 2.4
B09 2 2.51 23.8 96.3 97.3 99.3 1.1
B10 2.65 2.51 20.2 71.1 88.2 91.7 2.8
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3.B | Dose calculation gamma pass rate
3.B.1 | Gradient verification
Gamma index pass rates for all five plans calculated in the Tomo-
Phant are given in Table 1. With the 2.5 cm field, the pass rate is
high (99.8%) for the 6 cm and 10 cm target. For the 2 cm target,
the index tolerance must be increased to 3 mm/4%. Note that this
case was designed for testing purposes. In clinical practice, it would
not make sense to try to cover a 2 cm long PTV with the 2.5 cm
wide field and the 1 cm field would have been used instead.
The gamma pass rates of the plans calculated with the 5 cm field
are lower, below 90% for the 2 mm/3% tolerance. As can be seen in
Fig. 4 (b), the dose calculation is perturbed over 5 cm by the approx-
imation of the varying field width profile. Though, this figure also
shows that calculation of the field gradient by CheckTomo matches
well that of the TPS both in space and dose.
3.B.2 | Real patient cases and errors detection
The calculation of 29,791 dose points for one case takes between 2
and 3 minutes on Intel Core i5 3.4 GHz processor, depending on the
size of the region of interest considered.
CheckTomo was tested on 10 abdomen and pelvis, 10 head and
neck (H&N), and 10 breast plans. For each case, the mean dose dif-
ference (DD) and global gamma comparison tests between the
CheckTomo and the tomotherapy TPS dose distributions were calcu-
lated. Individual results of all cases are provided in Tables 2–4. For
each location and tolerances, the number of plans that succeed the
gamma test (Nc>95%, i.e., pass rate above 95%) and the mean gamma
pass rate (c) over the 10 plans are given in Table 5. One can see that
plans in the abdominal and pelvic region are the most accurately cal-
culated with at least 7 plans out of 10 succeeding the gamma com-
parison test. In the opposite, dose calculation for the H&N cases is
F I G . 3 . Relative jaw penumbral filters of
the 2.5 cm (a) and 5 cm (b) nominal fields
for each of the three off-axis edge field
widths sampled, along the machine
longitudinal (IEC-y) axis. RJPF are shown at
depth 1.5 cm (solid lines) and 10 cm
(dashed lines).
F I G . 4 . Dose profiles of the plans
calculated in the TomoPhant for varying
PTV length, for the 2.5 cm field width (a)
and 5 cm (b). Plain line corresponds to the
dose calculated by the tomotherapy TPS
and dots to CheckTomo dose points.
F I G . 2 . Longitudinal profiles, along the machine IEC-y axis, of the 2.5 cm (a) and 5 cm (b) on-axis nominal fields (black) and their related off-
axis edge fields (colored). Dots represent measurements, plain lines the edge profiles calculated from Eq. (3). Measurements were performed at
1.5 cm depth, all leaves open, on the positive IEC-y side of the gantry. Values in the legend correspond to the field width at isocenter.
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more prone to errors and requires the gamma index dose tolerance
to be increased to 4% to have a majority of plans succeeding the
test. This can be explained by the fact that PTVs in the abdominal
and the pelvic area usually encompass large homogenous tissue vol-
umes, while bones and air cavities can be found in the H&N region.
The difference of calculation accuracy between those two kinds of
location comes from the fact that the dose calculation in CheckTomo
relies on a water-based model, which is obviously more reliable in
tissues with densities close to water. Note that the scope of this
manuscript is to describe the implementation of TomoEDGE in
CheckTomo, not to suggest improvements of its calculation engine.
Concerning the breast cases, where the target volumes are often
off-axis, increasing the number of subprojections per projection from
1 to 3 or 5 could improve the results accuracy.6
Table 6 shows the results of the error simulation tests. It con-
cerns 15 cases that had passed the 2 mm/3% gamma comparison
test. As one can see, all plans failed the 2 mm/3% gamma test when
a 4 mm shift was applied longitudinally to the calculation grid or if
the dose was offset by 3%.
The results of the gamma comparison tests presented here for
dynamic cases are similar to what had been obtained for static jaws
plans with the original release of CheckTomo.3 In other words, the
overall dose calculation accuracy and sensitivity to errors is equiva-
lent for both TomoEDGE and non-TomoEDGE plans.
Performing an independent dose calculation with CheckTomo is
not as comprehensive as actually measuring it during a QA proce-
dure, in that sense that it performs no control on the machine side.
Though, CheckTomo successfully detected simulated errors exceed-
ing tolerances. In other words, it is conservative of the quality assur-
ance, thus can provide a good indicator of the accuracy of the dose
calculation. Nonetheless, the way CheckTomo could be used in
practice (e.g., replace a patient QA measurements) remains the
responsibility of the local medical physicist.
3.C | Occasional edge dose calculation error
In some cases, the dose is over or under estimated in the target vol-
ume edges, as shown in Fig. 5 left-hand side. The occurrence of
such errors seems random and is caused by rounding mistakes in the
calculation of the dose grid coordinates. Even a submillimetric regis-
tration error between the CheckTomo and tomotherapy TPS dose
distributions could lead to a dose miscalculation of several Gy within
the high gradient region. Though, such a problem can be easily
addressed by shifting longitudinally the TPS dose volume, using a
manual registration tool included in CheckTomo since the first ver-
sion. As it happens, the error appearing in Fig. 5 was corrected by
applying a 1 mm shift. The result is shown on the figure right-hand
side.
Even if such an error is not accounted for, it does not much
impact the overall gamma pass rate of the plan (0.3% in the case of
Fig. 5). The relative dose difference does usually not exceed 10%
and concerns only the points located in the field edges, hence a
small portion of the PTV. However, one should note that Check-
Tomo was not specifically designed to be a dose gradient verification
tool and should not try to use it as such. CheckTomo cannot isolate
a particular region of interest and lacks analysis tools dedicated to
conformality verification.9
4 | CONCLUSION
CheckTomo software for independent dose calculation in tomother-
apy was upgraded for TomoEDGE treatments by introducing the
RPJF in its profile calculation model. It was noted that this method
implies that a slight inaccuracy in the edge field profiles calculation
has to be tolerated. The results of the gamma comparison tests
demonstrated that, in terms of dose calculation accuracy and errors
detection, the upgraded version of CheckTomo is as reliable for
dynamic jaws plans as the former release was for static cases. This
leads us to conclude that, from now on, CheckTomo offers the
opportunity to perform independent dose calculation equivalently
for both static and dynamic jaws tomotherapy plans.
TAB L E 6 Number of cases succeeding the gamma test (Nc>95%),
mean pass rate (c), and average mean dose difference (DD) for 15
treatment plans on which was applied a longitudinal shift of 2 and 4
mm and a dose offset of 3%. Only plans which had passed (without
simulated error) a 2 mm/3% gamma test were considered.
Unshifted 2 mm shift 4 mm shift Overdosage 3 %
Nc>95% [%] 15 13 0 0
c [%] 98 96.7 83.7 63.2
DD [%] 0.79 0.77 0.91 3.49
F I G . 5 . Coronal view of the relative
difference, given in percent, between the
CheckTomo and the tomotherapy TPS
dose of a pelvis plan. As one can see in
figure (a), the dose is miscalculated in both
edges of the target volume. The error is
corrected by applying a 1 mm shift in the
longitudinal direction (IEC-y) to the TPS
dose distribution, as shown in figure (b).
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Purpose: We developed an algorithm to measure the leaf open times (LOT) from the on-board detec-
tor (OBD) pulse-by-pulse data in tomotherapy. We assessed the feasibility of measuring the LOTs in
dynamic jaw mode and validated the algorithm on machine QA and clinical data. Knowledge of the
actual LOTs is a basis toward calculating the delivered dose and performing efficient phantom-less
delivery quality assurance (DQA) controls of the multileaf collimator (MLC). In tomotherapy, the
quality of the delivered dose depends on the correct performance of the MLC, hence on the accuracy
of the LOTs.
Materials and methods: In the detector signal, the period of time during which a leaf is open corre-
sponds to a high intensity region. The algorithm described here locally normalizes the detector signal
and measures the FWHM of the high intensity regions.
The Daily QA module of the TomoTherapy Quality Assurance (TQA) tool measures LOT errors.
The Daily QA detector data were collected during 9 days on two tomotherapy units. The errors
yielded by the method were compared to these reported by the Daily QA module.
In addition, clinical data were acquired on the two units (25 plans in total), in air without attenuation
material in the beam path and in vivo during a treatment fraction. The study included plans with fields
of all existing sizes (1.05, 2.51, 5.05 cm). The collimator jaws were in dynamic mode (TomoED-
GETM). The feasibility of measuring the LOTs was assessed with respect to the jaw aperture.
Results: The mean discrepancy between LOTs measured by the algorithm and those measured by
TQA was of 0 ms, with a standard deviation of 0.3 ms. The LOT measured by the method had thus
an uncertainty of 1 ms with a confidence level of 99%.
In 5.05 cm dynamic jaw procedures, the detector is in the beam umbra at the beginning and at the
end of the delivery. In such procedures, the algorithm could not measure the LOTs at jaw apertures
between 7 and maximum 12.4 mm. Otherwise, no measurement error due to the jaw movement was
observed. No LOT measurement difference between air and in vivo data was observed either.
Conclusion: The method we propose is reliable. It can equivalently measure the LOTs from data
acquired in air or in vivo. It handles fully the static procedures and the 2.51 cm dynamic procedures.
It handles partially the 5.05 cm dynamic procedures. The limitation was evaluated with respect to the
jaw aperture. © 2019 American Association of Physicists in Medicine [https://doi.org/10.1002/
mp.13459]
Key words: leaf open time, machine QA, tomotherapy
1. INTRODUCTION
Intensity-modulated radiation therapy (IMRT) is a widely used
treatment modality.1 It enables the delivery of highly inhomo-
geneous dose distributions. Because of this inherent complex-
ity, international guidelines recommend performing systematic
pretreatment delivery quality assurance (DQA) controls of
IMRT plans.2,3 The most common DQA protocols involve
measuring a dose distribution in a virtual water phantom using
a film, ion-chambers, or a detector array. The quality of the
measured distribution is usually assessed through statistical
criteria (e.g., a c-index percent pass rate4). These protocols
verify the overall correspondence between the planned and the
delivered dose. Their advantage is that they provide a check of
the overall performance of the treatment unit.
The most commonly used pretreatment DQA protocols
present three major drawbacks. First, the phantom-based
measurements are usually time consuming. Phantom setup,
positioning, and other repetitive tasks are carried out manu-
ally. An automated phantom-less protocol would lighten the
1 Med. Phys. 0 (0), xxxx 0094-2405/xxxx/0(0)/1/xx © 2019 American Association of Physicists in Medicine 1
workload. Second, the usual acceptance criteria may not be
suitable for dose error detection, especially when incorrectly
used.5–9 Another option would be to calculate the delivered
dose on the patient planning images using the fluence mea-
sured inline by the treatment system. It would make it possi-
ble to use dose-oriented criteria, which are more reliable.5
Third, there is no control of the individual treatment frac-
tions. A comprehensive DQA tool would work in vivo.
Tomotherapy (Accuray Inc., Sunnyvale, CA, USA) is a
topographic and helical IMRT system. It provides image
guided radiation therapy by megavoltage computed tomogra-
phy (MVCT). The on-board MVCT detector (OBD) is
mounted opposite to the LINAC on the gantry ring. It mea-
sures the exit fluence per LINAC pulse during imaging and
treatment delivery. The binary multileaf collimator (MLC)
modulates the beam. The open times of the MLC leaves are
optimized to reach the desired dose distribution.
Delivered dose accuracy and patient safety depend on the
MLC performance, i.e., on the correctness of the leaf open
times (LOT). The manufacturer has implemented mecha-
nisms to prevent severe MLC failures, yet, it tolerates smaller
errors. These can lead to observable dose discrepancies,10–14
but phantom-based DQA procedures do not evaluate the
actual dose distribution inside the patient.
Some authors have used the detector data to measure the
LOTs.14–17 Others used the exit fluence to verify MLC opera-
tion18–20 or to reconstruct the delivered dose without measur-
ing the LOTs.11,21–23 Handsfield et al.12 and Deshpande
et al.14 calculated the delivered dose from the measured
LOTs. Handsfield et al.12 used the method described by Chen
et al.15 to measure the LOTs. They calculated the delivered
dose of individual treatment fractions for some patients.
Around a decade ago, Accuray started developing a
dynamic jaw mode. It allows changing the field size and
shifting the field longitudinally during treatments.24 In 2012,
Accuray released the TomoEDGETM feature. It reduces the
penumbra on the target cranial and caudal edges. Dynamic
jaw delivery is intended to offer more possibilities in the
future, e.g., motion management.25 However, when the field
edge is too distant from the source axis, the beam is off the
detector. Thus, only the scattered fluence is recorded. It may
be impossible to measure the LOTs or to reconstruct the dose
from the detector raw data at certain jaw apertures.
As stated above, in tomotherapy, the MLC performance is
a major concern for dose accuracy and safety. What is more,
dynamic jaw delivery is obviously becoming the standard.
Therefore, there is a strong interest in measuring the LOTs in
air and in vivo, for both the static and the dynamic jaw
modes. As far as we know, only Chen et al.15 have measured
the LOTs in air and in vivo. Their method was designed to
handle static jaw procedures because TomoEDGETM had not
been released at that time.
As is highlighted in the present paper, detector data col-
lected under dynamic jaws cannot be parsed as data collected
under static jaws. Therefore, we developed an algorithm that
aims to measure the LOTs from the detector pulse-by-pulse
data of both static and dynamic jaw procedures. It is based on
the work of Chen et al.15 We assessed in which segments of
the dynamic jaw procedures the algorithm could reliably
measure the LOTs. We validated the algorithm on machine
QA data and on a broad sample of clinical treatment data
acquired both in air and in vivo under all jaw settings.
2. MATERIALS AND METHODS
2.A. Tomotherapy system
All data used in this study were collected in our institution
on two TomoHDATM units, hereafter called TOMO1 and
TOMO2. Both these units offer every delivery mode, i.e.,
helical or topographic delivery with either static or dynamic
jaws.
2.A.1. Multileaf collimator and leaf open time
Tomotherapy units use a binary MLC with 64 leaves for
beam modulation. The leaves can only be in an open or a
closed position, and the beam modulation consists of varying
the LOTs. The leaves are activated by compressed air. This
allows for a fast travel — around 10 ms — between the two
positions.
In helical mode, the gantry rotations are split into 51 sectors.
A sector is called a sinogram projection. It extends over 7.06°.
The rotation period depends on the target dose, the pitch, and
the field size. It is fixed between 12 and 60 s. Equivalently, the
projection time is fixed between 235 and 1176 ms.
The LOTs are optimized across the projections. They
range from an arbitrary minimum threshold to the projection
time. The threshold is set in the jaw accelerator machine
(JAM) settings. On our units, it is 18 ms.
2.A.2. Leaf latency, sinograms, and leaf motion
advance
The leaves need some time to move from one position to
the other once a motion command is issued. This phe-
nomenon is called leaf latency. The maximum latencies
admitted are specified in the machine calibration parameters.
On our units, they are set to 70 ms. The latency causes varia-
tions of the effective LOTs. The average variation is measured
and adjusted accordingly in the JAM settings. The treatment
planning system (TPS) considers it.
The MLC sinogram is a matrix with a line per leaf and a
row per projection. It provides the LOTs. The sinogram of
any treatment plan exists in two versions. One is “machine
specific”. It contains the LOTs corrected of the variation
caused by the latency. It is meant for a correct delivery of the
planned fluence. The other is “machine agnostic”. It contains
the optimal LOTs used for dose calculation. When delivering,
the actual LOTs should ideally be equal to the optimal LOTs.
The leaves are planned to open and close symmetrically
(in time and angle) around the projection center. Yet in prac-
tice, the leaves move before their planned motion time. It is
not clear to us why, but we suspect that it must help to reduce
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the apparent latencies. Daily QA, a module of the TomoTher-
apy Quality Assurance (TQA) tool,26 measures the leaf
motion advance on a daily basis. It reports that the leaves
effectively move ahead of their planned open or close point
of time by 5–20 ms (2–6 LINAC pulses). The effective
advance varies from leaf to leaf and projection to projection.
2.A.3. On-board MVCT detector and pulse-by-pulse
data
Tomotherapy units employ MVCT detector arrays. These
are made up of ionization chambers filled with high-pressure
xenon, separated by tungsten septa. Our units have detectors
of different generations and from different manufacturers: GE
(General Electric, Boston, MA, USA) on TOMO1 and Hita-
chi (Hitachi Ltd., Chiyoda, Tokyo, JP) on TOMO2. Both
detectors possess 640 chambers. They differ in chamber size
(1.219 and 1.250 mm, respectively), distance from surface to
center (20 and 4 mm, respectively), and radius of curvature
(110.99 and 99.8 cm, respectively).
The detector measures the fluence exiting the patient per
LINAC pulse, i.e., at 80 Hz during imaging and 300 Hz during
treatment. These are the pulse-by-pulse data or uncompressed
raw data. The detector measurements are stable in time.27
The radiation delivery system (RDS) collects the raw data.
It stores them temporarily on the machine’s on-board computer
in a binary file. It erases them when a new delivery procedure
is loaded. The raw data file can be retrieved via FTP after the
procedure delivery. It contains an array with a line-per-pulse
and a column-per-channel, along with other information.
2.A.4. Field size and jaw mode
The collimator jaws delimit the field size along the
patient’s longitudinal direction. The jaw aperture (projected
in the isocenter plane) is preset to either 7, 20, or 42 mm,
resulting in a field FWHM of 1.05, 2.51, or 5.05 cm. The jaw
presets are commonly referred to as J07, J20, and J42.
TomoEDGETM is the only feature based on the dynamic jaw
mode to have been released so far. It is available for the J20
and the J42 presets. It is meant to reduce the dose penumbra
on the target region cranial and caudal edges.24
At the beginning and at the end of dynamic procedures,
the jaws are located on the same side of the source axis.
Under the J42 preset, the jaws cross up to 14 mm (in projec-
tion in the isocenter plane) over the axis. The detector is thus
momentarily in the beam umbra at the beginning and at the
end of these procedures.
2.A.5. Leaf spread functions and channel to leaf
mapping
The leaf width at isocenter (6.25 mm) is greater than the
detector channel width. The beamlet issued from a single leaf
covers multiple detector channels. Which is more, the signal
measured by the detector is the convolution product of the beam
profile and the detector response to the incoming fluence.
We measured the beam spreading from each leaf at the
three preset jaw apertures (7, 20, and 42 mm) and at the
narrower apertures of 7, 9, 11, 13, 15, and 17 mm of the
J20 and J42 presets on both sides of the source axis.
From the detector signal (the beam profiles convoluted to
the detector response), we determined a leaf spread func-
tion (LSF) for each leaf and each jaw positions. We fitted
a sum of Gaussian functions on each signal. We measured
and subtracted the background signal (caused by MLC
leakage and detector dark current) at each jaw position
individually.
A bijective leaf-to-channel map was determined by match-
ing a leaf to the center of the beamlet it produced. To deter-
mine the leaves state, it is sufficient to observe the signal at
these specific channels.14,15,17
2.A.6. TomoTherapy Quality Assurance Daily QA
module
The Daily QA module of TQA performs various machine
tests. In particular, it runs two LOT tests. In the first, the
leaves open 8 by 8 during 50, 100, 150, and 200 ms. In the
second, all the 64 leaves open simultaneously during 100 and
150 ms. In both tests, the projection time is 200 ms and the
jaws are static. The module calculates and reports the LOT
error for each leaf and each test.
In Daily QA, the commended LOTs were set such that the
leaf should operate normally. No leaf should fail to open and
no leaf should fail to close between two successive projec-
tions. If the commended LOTs were shorter (less than 30 ms)
or larger (within 30 ms of the projection time), large LOT
errors (greater than 15 ms) could occur.15,28,29
2.B. Leaf open time calculation from raw data
In the detector signal, the period during which a leaf is
open corresponds to a distinct peak or a higher intensity
region (Fig. 1). The related LOT can be calculated by
determining the region width. In the following sections,
we present our calculation algorithm. It relies on an in-
house function written in Python to read the data from
the binary files into NumPy arrays.30 It outputs a sino-
gram of the plan sinogram size providing the measured
LOTs.
The algorithm works in three steps (Fig. 2). First, it cor-
rects the signal from arcings and deconvolve the signal
spreading from leaves to leaves (Section 2.B.1). Then, it
determines at each projection individually which leaves have
opened and which have not, and it normalizes the signal
locally (Section 2.B.2). Finally, it determines the edges of the
open leaf regions and calculates the related LOTs (Sec-
tion 2.B.3).
2.B.1. Raw data preprocessing
When an electrical arcing happens in the LINAC, the
detector records a short and steep drop of the beam intensity.
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That intensity drop can be confused with a leaf closing
briefly before opening again. Therefore, the algorithm cor-
rects the raw data whenever an arcing occurs. It interpolates
temporally the impacted pulses with their neighbors. Arcings
can be easily identified by observing the time derivative of
the monitor chambers signal.
The raw data are interpolated at the 64 leaf specific chan-
nels according to the channel-to-leaf map (c.f., Sec-
tion 2.A.5). Then, the algorithm calculates the background
signal for each leaf over the machine warm-up pulses, and
subtracts it.
The beamlet of a leaf spreads over the detector, i.e., an
open leaf creates a parasitic signal in its neighbors’ channel.
To prevent this contamination from inducing LOT measure-
ment errors, the algorithm corrects it by applying the iterative
deconvolution of Richardson-Lucy,31,32 as proposed by Chen
et al.15
Let us we write Lij the value of leaf i spread function at the
specific channel of leaf j (c.f., Section 2.A.5). Lij is the frac-
tion of leaf i signal measured in leaf j channel. Writing di the
detector signal measured under leaf i during any specific
pulse, the Richardson–Lucy algorithm yields
d^tþ1i ¼ d^ti
X
j
LjidjP
k Ljkd^
t
k
(1)
t is the iteration step and d^ is the estimate of d under the
deconvolution.
Finally, for calculation purpose, the data are binned per
sinogram projection. They are handled as a three-dimensional
matrix, written Dlpi hereafter. The indices l, p, and i represent
the leaf, the projection, and the pulse, respectively. Data are
resampled if the number of pulses per projection is not
integer.
2.B.2. Signal normalization
The data corresponding to leaf l at projection p should be
normalized locally only if leaf l has actually opened during
projection p. Otherwise, one would just amplify the noise.
Therefore, the algorithm determines at each projection the
leaves that have opened and normalizes only the data parts
related to opening leaves.
To detect the opening leaves, the algorithm relies on a pro-
jection-dependent threshold. It defines a thresholding value
per projection. On static jaw procedures, a single threshold
value applied on the entire signal was suitable.15 In dynamic
jaw mode, however, the threshold must account for the signal
intensity drop at the beginning and at the end of the proce-
dures (Fig. 3). The detection works in two steps.
First, the algorithm detects the projections at which at least
one leaf has opened. It calculates the maximum signal mea-
sured per projection
~Dp ¼ maxliDlpi: (2)
When ~Dp is above a specific threshold sproj, we consider
that at least one leaf has opened during projection p. We used
sproj = 0.01.
Second, the algorithm detects the opening leaves at each
of the projections it has selected at the first step. It discards
the projections without opening leaves. At a particular pro-
jection p, it calculates the maximum signal measured per leaf
~Dlp ¼ maxiDlpi: (3)
When
~Dlp[ sleaf ~DpÞ

(4)
(a) (b)
FIG. 1. Detector signal after deconvolution (solid lines) and raw signal (dashed lines) of leaf 40 (a) and leaf 26 (b). In vivo data from patient 1 treatment (c.f.
Table I). The signal is plot over seven sinogram projections. The dotted vertical lines correspond to the projection boundaries. Areas in gray correspond to the
periods during which the leaves were planned to be open. (a) The planned LOTs were short, between 19 and 61 ms. (b) The planned LOTs were of 475 ms (the
projection time) at projections 70, 71, 72, and 74. They were of 433 and 436 ms at projections 73 and 75, respectively.
FIG. 2. Workflow of the LOT calculation algorithm.
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we consider that leaf l has opened during projection p. The
threshold sleaf is a piecewise linear function of tildeDp.
Finally, the algorithm normalizes the raw data per leaf and
per projection. If leaf l was detected to have opened during
projection p, the corresponding data are normalized by ~Dlp.
The algorithm accounts for the pulses possibly binned in the
wrong projection (see Section 2.A.2).
2.B.3. Open time calculation
As stated in the introduction of Section 2.B, the period
during which a leaf is open corresponds to a peak or a higher
intensity region in the detector signal. To calculate the LOT,
the algorithm determines the leaf opening and closing points
of time. We have defined them as the two points at which the
signal crosses a specific threshold soc. We have fixed soc at
0.5. In this case, the LOTs correspond to the FWHM of the
open leaf regions. The signal is linearly interpolated to get a
finer precision than the measurement sampling of 3.3 ms.
Others took a similar approach.15,17
A leaf may stay open across multiple projections [e.g.,
from projection 70–75 in Fig. 1(b)]. Because leaves move
ahead of the planned time (c.f. Section 2.A.2), the open leaf
region may span over the boundary of the first projection [in
Fig. 1(b), the open leaf portion of the signal spans in projec-
tion 69]. In these cases, the algorithm shifts the signal region
by the mean leaf motion advance observed over the whole
procedure. Then, the region is split per projection.
2.C. Algorithm validation
We collected machine TQA data (Section 2.A.6) and clin-
ical data to validate the LOT measurement algorithm. We col-
lected the Daily QA raw data and test results on both our
treatment units each Monday during 9 weeks. We collected
clinical in air and in vivo (one treatment fraction) data from
25 patient treatments (Table I). The in air measurements con-
sisted of delivering the DQA procedure without anything in
the beam path (except the couch). In vivo measurements miss
for plans 8 and 9. In total, 48 datasets were available. J20 and
J42 procedures were always in dynamic jaw mode.
FIG. 3. Maximum detector signal per sinogram projection ~Dlp (3) after
Richardson–Lucy deconvolution. In vivo data from patient 20 treatment (c.f.
Table I). The data of two leaves are represented as a function of the jaw aper-
ture, from the moment the jaws started opening (aperture of 7 mm) until they
reached their maximal aperture (42 mm). Leaf 36 signal dropped near 21,
22, and 34 mm because leaf 36 was actually closed throughout the entire cor-
responding projections; it is not an artifact of the algorithm. The magnifica-
tion shows the signal of the same leaves at all pulses, at a jaw aperture from
8.2 to 9.5 mm (projections 45–50). Leaf 35 opened at each of these six pro-
jections and leaf 36 stayed closed. The dashed line in both plots is the thresh-
old sleaf used in (4).
TABLE I. Summary of the treatment plans used to collect data, split by treatment unit. The projection and duration columns give the plan projection time and the
procedure total duration, respectively.
TOMO1 TOMO2
Patient Localization Jaw Proj. (ms) Duration (s) Patient Localization Jaw Proj. (ms) Duration (s)
2 Thorax J20 424 384.6 1 Mediastinum, left J20 475 316.0
3 Lung, left J20 333 249.0 9* Mediastinum J42 498 397.9
4 Thorax J20 947 608.0 10 Breast, right J42 614 562.8
5 Skull J20 231 149.7 11 Lumbar vertebrae J42 433 363.6
6 Skull J20 294 191.5 13 Vertebra T12 J42 845 314.4
7 Rib, right J07 690 540.4 14 Esophagus J42 600 714.0
8* Mediastinum J42 314 292.7 15 Vertebrae L3 to L4 J42 535 171.3
18 Skull, peduncle J07 418 460.7 16 Skull J07 231 522.7
19 Skull, frontal J07 633 270.4 17 Eye, right J07 420 489.7
20 Vertebra T9 J42 357 149.5 24 Head & Neck J20 231 310.7
21 Vertebrae L1 to L3 J42 412 261.1
22 Vertebrae T3 to T6 J42 369 230.8
23 Vertebra T11 to L3 J42 476 373.6
26 Pelvis J20 231 159.9
27 Head & Neck J20 288 309.0
*No in vivo data.
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We compared the LOT errors measured by our method to
the errors reported by the Daily QA module to perform a basic
algorithm verification (Section 2.C.1). We used clinical data to
determine at which jaw aperture the LOT measurement was
feasible in dynamic jaw mode and to verify whether it was
independent of the jaw aperture (Section 2.C.2). Again using
clinical data, we reviewed some parts of the raw signal to
ensure that large discrepancies between planned and measured
LOTs were no algorithmic errors and we verified that the LOTs
were measured equivalently in air and in vivo (Section 2.C.3).
2.C.1. Comparison to Daily QA and measurement
uncertainty
Comparing the LOT errors measured by our algorithm to
the errors reported by Daily QA allowed us to validate the
LOT measurement against an accepted reference in
controlled conditions. Daily QA is performed in air with
static jaws. The leaves should operate normally (see
Section 2.A.6).
Additionally, we estimated the variability of the leaf
motion advance (c.f., Section 2.A.2) from the Daily QA raw
data and estimated the LOT measurement uncertainty.
2.C.2. Leaf open time measurement in dynamic jaw
segments
We investigated whether measurement errors occurred at
the beginning and at the end of dynamic procedures. In par-
ticular, the J42 data measured when the beam was off the
detector (Section 2.A.4) might be unexploitable. The unex-
ploitable data segments were determined by looking at the
differences between planned and measured LOTs. As actual
discrepancies are reported up to 45 ms,15 we considered that
absolute differences greater than 50 ms were likely errors of
the algorithm. We looked for the maximal jaw aperture at
which such errors occurred on each J20 and J42 datasets. We
measured the relative length of the unexploitable segments
respectively to the total treatment length.
We tested whether the LOT measurement depended on the
jaw aperture in dynamic procedures. We grouped the data by
jaw preset (J20 or J42), by treatment unit (TOMO1 or
TOMO2), and by collection type (in air or in vivo). For each
group, we calculated the differences between planned and
measured LOTs. Then, we looked for a correlation between
the differences and the jaw aperture. We calculated the slid-
ing mean and standard deviation of the differences as a func-
tion of the jaw aperture, with a window of 1 mm.
2.C.3. Leaf open time discrepancies and in air and
in vivo comparison
We calculated the discrepancies between planned and
measured LOTs for clinical datasets. If segments of the
dynamic jaw procedures were considered as unexploitable,
then they were discarded. The LOT measurement on these
segments would be unreliable.
We reviewed manually the raw signal when the absolute
difference between the planned and the measured LOT was
greater than 15 ms. We verified that the signal was not cor-
rupted, e.g., by excessive noise or by arcings in the LINAC.
We verified that the algorithm measured the same LOTs in
air and in vivo. For each patient, we generated the distribution
of the discrepancies measured in air and the distribution of
the discrepancies measured in vivo. Then, we compared the
two distributions.
3. RESULTS
The Richardson–Lucy algorithm executed within 20–60 s,
depending on the procedure length, on a standard desktop
computer. The execution time of the subsequent algorithm
steps was negligible.
3.A. Leaf spread functions
Under the J42 preset, the LSFs got broader as the jaw
closed (Fig. 4). Conversely, the LSFs were independent of
the jaw aperture under the J20 preset.
The LSFs fitting errors were always less than 2% at the
three preset jaw apertures. They were less than 3% at the nar-
rower apertures of the J42 preset.
3.B. Comparison to Daily QA and measurement
uncertainty
We calculated the differences between the LOT errors
measured using our method and the errors reported by Daily
QA. The mean difference was 0.0 ms and the standard devia-
tions was 0.3 ms on both our tomotherapy units. The
maximum difference was 1.7 ms. Regarding the standard
deviations, the algorithm measured the LOTs with an uncer-
tainty of 1 ms at a confidence level of 99%.
The mean standard deviation of the leaf movement
advance was of 0.7 LINAC pulse, or 2.2 ms. When a leaf
FIG. 4. Raw data (lines) and fit (cross markers) of leaf 31 spread functions at
three different jaw apertures of the J42 preset measured on unit TOMO1. The
fit is represented only at the neighbor leaves’ channels.
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stays open across multiple projections, the uncertainty on the
first and on the last projection LOTs is higher. The measured
LOTs have then an uncertainty of 6 ms at a confidence level
of 99%.
3.C. Leaf open time measurement in dynamic jaw
segments
On J20 procedures, we observed no LOT differences
greater than 50 ms. On J42 procedures, we observed differ-
ences greater than 50 ms up to a jaw aperture of 12.4 mm
(Table II). There was no significant difference between in air
and in vivo measurements. The unexploitable segments repre-
sented between 3.4 and 14.4% of the total treatment length
(Table II).
Figure 3 illustrates the signal drop at the beginning of a
J42 procedure. It illustrates that it was sometimes impossible
to distinguish an open leaf signal from the noise at apertures
below 13 mm. In particular, at jaw apertures between 8.2 and
9.5 mm (magnified in Fig. 3), leaf 35 opened at all projec-
tions while leaf 36 stayed closed. Yet, the signals of leaves 35
and 36 are identical at most of these projections.
Figure 5 shows the differences between planned and mea-
sured LOTs for the J20 procedures and the J42 procedures
measured in vivo on TOMO1. It shows the sliding mean and
sliding standard deviation calculated over a window of 1 mm.
In J20 procedures and above 12 mm in J42 procedures, nei-
ther the mean nor the standard deviation correlated with the
jaw aperture. We made the same observation for the data
measured in air and on TOMO2.
3.D. Leaf open time discrepancies and in air and
in vivo comparison
In the processing of J42 data, we discarded the projections
at which the jaw aperture was below 13 mm. We had found
unexploitable data segments up to 12.4 mm (Section 3.C).
Figure 6 shows the distributions of the discrepancies between
planned and measured LOTs. The largest discrepancies were
always less than 45 ms.
We looked at the planned LOTs and signal segments cor-
responding to the largest discrepancies. In some instances,
the measured LOT was more than 15 ms shorter than
expected. Then, the planned LOTwas below 30 ms. In these
situations, no peaks— or only traces of them— were visible
in the raw signal [e.g., projections 206, 210, and 212 in
Fig. 1(a)]. Similarly, the measured LOTwas more than 15 ms
larger than expected in some other instances. The corre-
sponding planned LOT was within 45 ms of the projection
time in two successive projections at least. In these situations,
we observed that the signal did not drop — or only partially
— between the projections [e.g., projections 73 and 75 in
Fig. 1(b)].
Considering any specific procedure, the in air and
in vivo discrepancy distributions had similar shapes. The
means were within 0.5 ms of each other, except for
patient 1 and 5. In these instances, the difference
between both means was 0.9 and 3.5 ms, respectively.
The distributions were only shifted relatively to each
other. They still had the same shape. In particular, the
interquartile range (IQR) did not change.
TABLE II. Maximal jaw aperture (mm) under which LOT differences greater than 50 ms were measured on the in air and in vivo J42 procedures’ data. Lines TTT
fraction and Dynamic jaw fraction give the fraction of the total treatment length and of the dynamic jaw segments, respectively, in which the data were unex-
ploitable.
TOMO1 TOMO2
Patient 8 20 21 22 23 9 10 11 13 14 15
In air 11.2 11.1 11.2 11.2 11.3 10.5 10.6 10.7 10.6 9.0 11.0
In vivo 11.8 11.0 11.0 11.3 12.4 10.1 10.6 9.7 11.2
TTT fraction (%) 6.2 14.4 9.2 5.9 7.3 7.1 5.8 5.4 13.1 3.4 8.0
Dynamic jaw fraction (%) 17.1 17.0 17.1 11.4 17.3 16.7 16.5 13.8 14.6 12.3 11.5
(a) (b)
FIG. 5. Differences between planned and measured LOTs as a function of the jaw aperture. All the J20 (a) and J42 (b) in vivo data collected on TOMO1 were
grouped together. The white line is the sliding mean of the differences for a window of 1 mm. The gray area corresponds three times the sliding standard devia-
tion (same window).
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4. DISCUSSION
Here we present a method to measure the LOTs from the
uncompressed detector raw data and its validation on two dif-
ferent tomotherapy units. The method aimed to extend previ-
ous works to the dynamic jaw mode. The results show that
detector data are not exploitable by our algorithm below a
jaw aperture of maximum 12.4 mm in dynamic J42 proce-
dures. However, they show that the LOTs were reliably mea-
sured both in air and in vivo under the other jaw settings.
Our work extends the previously proposed method for in
air and in vivo LOT measurement.15 We showed that the LSF
depend on the jaw aperture under the J42 preset (Fig. 4) and
incorporated these jaw-dependent functions in the algorithm.
Additionally, our algorithm uses a dynamically adapting
threshold to normalize the signal (Section 2.B.2). In dynamic
J42 procedures, the recorded signal always drops to zero as
the jaws closed (Fig. 3). The signal amplitude at 12 mm is of
the same order as the signal noise at 40 mm. Using the same
threshold at all jaw apertures would not be optimal. A static
threshold may also be suboptimal on dynamic J20 proce-
dures, especially in the presence of attenuation material.
The unexploitable data segments represented between
3.4% and 14.4% of the total treatment length. It would not be
responsible to discard 14% of the treatment projections of a
treatment plan during the DQA process. Yet, in such cases, it
is still possible to measure the LOTs at all projections in air
by delivering with fixed jaws. A procedure with fixed jaws
can be generated from the treatment plan. With respect to the
LOT measurement, this would not make any difference.
Changing the jaw mode does not modify the planned LOTs
and our algorithm does not verify the jaw positions anyway.
The local normalization wipes the jaw effect out of the signal
(Section 2.B.2). Moreover, the tolerated jaw motion uncer-
tainty has a low dosimetric impact and Daily QA checks the
jaw health regularly.
Analyzing more J42 plans could make it possible to high-
light, or not, a difference in the extent of the unexploitable
data segments between our two treatment units. The unex-
ploitable data extent could be detector dependent. In addition,
the segments size could be more formally expressed in terms
of the signal-to-noise ratio of the detector signal.
The discrepancies, between planned and measured LOTs,
greater than 15 ms were not algorithmic failures. The manual
review of the raw signal excluded this possibility. This high-
lights the limits of considering that the MLC is purely binary.
A leaf is only considered either fully closed or fully opened,
even while it is moving. This does not correspond to the real-
ity. A leaf might stay closed or open only partially when the
planned LOT is less than 30 ms [e.g., projections 206, 210,
and 212 in Fig. 1(a)]. Moreover, a leaf might stay opened or
close only partially when the planned LOTs are within 45 ms
of the projection time in at least two successive projections
[e.g., projections 73 and 75 in Fig. 1(b)].
The results indicate that, otherwise, the algorithm mea-
sured the LOTs reliably. The agreement between the LOTs
measured by the algorithm and by TQA was high, indicating
that the LOT measurement was reliable in air under static
jaws. Then, except at the signal segments reported as unex-
ploitable, the narrowing of the jaws did not increase the LOT
measurement uncertainty. The mean and standard deviation
of the differences between planned and measured LOTs did
not depend on the jaw aperture (Fig. 5). In the dynamic jaw
segments, the difference mean oscillated between 1.5 and
1.5 ms, which is comparable to the discrepancy means in the
J07 (static jaw) procedures (Fig. 6). Finally, the beam attenu-
ation and scattering caused by the patient did not increase the
measurement uncertainty either. The algorithm measured
equivalent LOTs in air and in vivo (Fig. 6). Therefore, as the
algorithm measured the LOTs reliably in air under static jaws,
independently of the jaw aperture, and independently of the
patient attenuation, we assess that it measured them reliably
in all situations.
The discrepancies we found between planned and mea-
sured LOTs are consistent with the findings of others.14–
17,28,29 We could not otherwise compare the method to an
external standard on clinical procedures, because there is
none. Chen et al.15 modified the RDS software to make it
record the output of the leaf position optical sensors. We did
not have this opportunity because we collected the data on
units in clinical use.
Our LOT measurement method can be the basis of a con-
venient pretreatment and in vivo DQA tool. A comprehensive
DQA protocol would verify the dose output and the patient
position. Accuray has started going in this direction with the
release of Delivery Analysis (2015), a detector data process-
ing software. Among others, Delivery Analysis provides a
pretreatment dose-based QA functionality relying on
FIG. 6. Violin plots of the discrepancies between planned and measured LOTs for all the procedures measured on TOMO1 (left) and TOMO2 (right). The hori-
zontal lines show the means, and the first and third quartiles. The labels J07, J20, and J42 correspond to the jaw settings. J42 data below a jaw aperture of 13 mm
were discarded.
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Accuray’s standalone dose calculator.33 As of today, Delivery
Analysis does not measure the LOTs of the projections
located in the dynamic jaw regions of the plan. Our algorithm
measures the leaf opening and closing points of time before
calculating the associated LOTs. It is thus compatible with
Accuray’s dose calculator.33
5. CONCLUSION
We developed a method to measure the LOTs from the
detector pulse-by-pulse data. The algorithm could not mea-
sure the LOTs on the first and last segments of the J42
dynamic jaw procedures at which the jaw aperture was the
narrowest (from 7 to maximum 12.4 mm). It measured the
LOTs otherwise reliably, with or without a patient on
the treatment couch.
The method we propose is a first step toward an efficient
pretreatment and in vivo DQA tool, and toward a more accu-
rate knowledge of the delivered dose in tomotherapy.
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Purpose: To validate a delivery quality assurance (DQA) protocol for tomotherapy based on the
measurement of the leaf open times (LOTs). In addition, to show the correlation between the mean
relative LOT discrepancy and the dose deviation in the planning target volume (PTV).
Materials and methods: We used a LOT measurement algorithm presented in a previous work.
We generated TomoPhant plans with intentional random LOT discrepancies following Gaussian
distributions of −6 %, −4 %, −2 %, 2 %, 4 %, and 6 %. We irradiated them on the Cheese Phantom
with two ion chambers and collected the raw data. Using the raw data, we measured the actual
LOTs and verified that the induced discrepancies were highlightable. Then we calculated the actual
dose using Accuray’s standalone calculator and verified that the calculated dose was in agreement
with the ion chamber measurements.
We chose randomly 60 clinical treatment plans and delivered them in air. We calculated the actual
LOTs from the raw data and calculated the actual dose using Accuray’s standalone calculator. We
assessed the correlation between the mean relative LOT discrepancy and the deviation between
expected and actual dose in the PTV.
Results: The mean relative LOT discrepancy measured by the algorithm on the modified Tomo-
Phant plans was within 1 % of the expected discrepancy. The measured and calculated dose agreed
within 1 %.
On clinical plans, the means of the relative LOT discrepancies ranged between −3.0 % and 1.4 %.
The dose deviation the PTVs ranged between −1.6 % and 2.4 %. The correlation between the mean
relative LOT discrepancy and the dose deviation in the PTV was of 0.76 on one treatment unit and
of 0.65 on another.
Conclusion: The method allowed to highlight correctly the LOT discrepancies on the TomoPhant
plans. The dose subsequently calculated was accurate. The mean LOT discrepancy correlated with
the dose deviation in the PTV. This makes the mean LOT discrepancy a handy indicator of the
plan quality.
I. INTRODUCTION
Pretreatment patient-specific delivery quality assur-
ance (DQA) is an essential, often mandatory step in the
intensity modulated radiotherapy (IMRT) workflow [1–
3]. It protects the patient against unexpected behaviours
of the treatment units that may lead to inadequate dose
delivery. Undesirable effects may range from poor cover-
ing of the planning target volume (PTV), hence reducing
the probability of complication-free tumour control, to
potentially lethal accidents.
Common pretreatment DQA protocols consists in mea-
suring the delivered dose in a phantom with films, ion-
chambers, or detector arrays. The dose quality is often
assessed using the γ-index pass rate [4]. These protocols
present some drawbacks. They are usually time consum-
ing and require to handle cumbersome phantoms. The
detector used may have angular dependence [5, 6]. And
above all, the γ-index pass rate has been reported to be a
poor predictor of the PTV dose, especially when applied
to dose distributions measured by detector arrays [7–15].
∗ mathieu.schopfer@chuv.ch
† raphael.moeckli@chuv.ch
Alternatives to measuring the dose in a phantom have
been proposed. One approach consists in using the logged
machine parameters – namely collimator position, gantry
angle, dose output, and patient position – to forward
calculate or reconstruct the actual dose in the patient’s
planning images [16–18]. This approach has the advan-
tage to provide more accurate knowledge of the actual
dose distribution in the patient’s anatomy.
In tomotherapy, the fluence is modulated by varying
the leaf open times and the jaw positions. During a treat-
ment, gantry rotation speed, couch translation speed,
and dose output are constant. Some authors have tested
the accuracy and stability of these parameters. Hands-
field et al. [19] have reported that couch positions and
gantry angles, as recorded by the data acquisition system
(DAS), corresponded to the planned values throughout
several treatment fractions. Lee et al. [20] have reported
a maximum jaw position error of 0.4 mm after repeating
a QA test over nine months. Finally, the dose control sys-
tem (DCS) is a servomechanism that stabilises the dose
output. The output was reported to variate within 0.4 %
[21].
In contrast, others have reported that the multileaf
collimator (MLC) is prone to fluctuations that may sig-
nificantly impact the quality of the delivered dose [19, 22–
225]. Which is more, neither the leaves state (open, close,
or moving) nor the leaves open times are recorded by the
DAS. In tomotherapy, a DQA based on the machine pa-
rameters should therefore focus on the MLC verification.
Other components can be checked by analysing the DAS
log files and through regular machine QA [26]. Daily
QA module of Tomotherapy Quality Assurance (TQA)
checks daily the health of the couch, the gantry, the jaws,
the LINAC (output and alignment), and the MLC [27].
In a previous article, we presented an algorithm to
measure the leaf open times (LOTs) from the detector
raw data [28]. Here we propose a DQA method for to-
motherapy based on the measured LOTs. We demon-
strate that the mean relative LOT discrepancy is a handy
indicator of the plan’s quality. On the Cheese Phantom,
we tested the method ability to highlight LOT discrep-
ancies and verified that the measured LOTs predicted
accurately the delivered dose. We used Accuray’s stan-
dalone calculator [29] to calculate the actual dose from
the measured LOTs and compared it to ion chamber mea-
surements. On clinical plans, we assessed that the mean
relative LOT discrepancy correlated with the dose varia-
tion in the PTV. Again, we relied on Accuray’s calculator
to calculate the expected and actual dose in the PTV.
In summary, we present a suitable and convenient DQA
method based on the LOTs measurement.
II. MATERIALS AND METHODS
Our department possesses two TomoHDATM units,
hereafter called TOMO1 and TOMO2.
A. Tomotherapy system and standalone dose
calculator
The tomotherapy binary MLC is designed to open and
close quickly its leaves. The typical leaf travel time is
around 10 ms. This allows for a fine modulation of the de-
livered fluence. Mechanical constraints may cause slight
variations of the actual leaf open time. The manufacturer
MLC interlock interrupts the irradiation when the delay
is larger than 70 ms. At low mean planned LOT, this
inaccuracy may lead to non-negligible dose discrepancy
[22].
Tomotherapy units uses megavoltage computed tomog-
raphy (MVCT) detector arrays for IGRT. During any
procedure (imaging, treatment, or DQA), the detector
collects the fluence per LINAC pulse (300 Hz). These
are the detector pulse-by-pulse data or uncompressed raw
data. They can be retrieved from the on-board computer
(OBC) after the procedure has been delivered.
Accuray’s standalone dose calculator can calculate
a dose distribution independently of the commissioned
treatment planning system (TPS). It needs to be pro-
vided with CT images, a tomotherapy procedure deliv-
ery plan, and a machine beam model [29]. Its software
FIG. 1. Cheese Phantom CT images and reference Tomo-
Phant plan dose (TOMO1) overlayed. The green lines corre-
spond to the machine axes.
suite include tools to retrieve images, plans, and machine
beam models from the patient archives.
B. Leaf open time measurement
In a previous work, we presented exhaustively an algo-
rithm to measure the leaf open times from the detector
raw data [28]. The algorithm performs a Richardson-
Lucy deconvolution of the signal. This allows us to get
a neat signal per leaf, without inter-leaf contamination.
Then, it normalises the signal locally to get rid off the
fluctuations due to the patient’s attenuation, the jaw out-
put, the leaves output, and the cone shape of the beam
profile. Then, the period of time during which a leaf is
open corresponds to a high intensity region of the nor-
malised signal. The algorithm thus measures the FWHM
of the high intensity regions.
C. Modified TomoPhant plans
To verify the ability of the leaf open time measure-
ment algorithm to detect discrepancies and to verify the
accuracy of the dose calculated from the measured LOTs
with Accuray’s standalone calculator [29], we modified a
TomoPhant plan.
TomoPhant is a set of synthetic plans used for routine
machine QA in tomotherapy. It allows to measure the
delivered dose with ion chambers in the Cheese Phantom
to verify its accuracy. We chose the helical plan with a
dynamic jaw field of 2.5 cm. These are the commonest
treatment settings in our department, because they allow
to reach the highest plan quality. This plan has two off-
axis cylindrical targets of 6 cm (figure 1). It is slightly
modulated, the mean planned LOT being of 173 ms for
projection time of 314 ms. This gave us enough mar-
3gin to introduce discrepancies without running into non-
deliverable LOTs. Which is more, few planned LOTs are
in the non-linear regimen of the leaves, i.e. below 30 ms
(where a leaf may fail to open) or within 30 ms of the
projection time (where a leaf may fail to close between
successive projections).
We generated random discrepancies following normal
distributions of mean −6 %, −4 %, −2 %, 2 %, 4 %,
and 6 %, and a standard deviation of 7 %. 7 % was
the mean standard deviation between planned and actual
LOTs observed in the clinical DQA (see section II D).
We chose Gaussian distributions because the discrepancy
distribution is a bell curve in many clinical instances [28].
No plan was generated with a mean difference of 0 %. We
modified only the LOTs, i.e. a leaf that does not open in
the reference plan does not open in any of the modified
plans either.
We delivered each plan twice (i.e. a total of 14 runs
per treatment unit). We collected the detector raw data
and measured the delivered dose. We used two A1Sl
ion chambers – one in each target – located at −0.5 cm
and +8.0 cm along the right-left axis (RTOG frame of
reference). From the detector raw data, we measured
the actual LOTs.
Hereafter, “reference” and “expected” LOTs refer to
original and modified TomoPhant plans, respectively.
For each measurement, we calculated the differences be-
tween actual and expected LOTs and the differences
mean and standard deviation. The differences between
actual and expected LOTs are caused by the intrinsic
MLC inaccuracy. Then, we calculated the expected dis-
crepancies (difference between expected and reference
LOTs) and the actual discrepancies (difference between
the actual and reference LOTs). Again, we calculated
the differences mean and standard deviation. Finally, we
calculated the actual dose from the actual LOTs and the
difference between calculated and measured doses.
In addition, we calculated the correlation between the
mean relative (actual) LOT discrepancy and the dose
difference (between measured and reference dose).
D. Clinical pretreatment DQA
To assess the correlation between the mean relative
leaf open time discrepancy and the dose deviation in the
PTV, we selected randomly 60 clinical treatment plans
(30 on each unit). All plans were helical, dynamic jaw
deliveries with a 2.5 cm field. These are the common-
est treatment settings in our department. All plans had
been accepted following the DQA protocol in use in our
department. This protocol consists in measuring the
dose with the Octavius 729 system (PTW, Freiburg, Ger-
many) and comparing measured and expected dose dis-
tributions using a 3D global γ-index in VeriSoft (PTW,
Freiburg, Germany), suppressing dose below 10-20 % of
expected dose maximum. The plan is accepted if the pass
rate (relative number of dose points verifying γ < 1) is
above 90 %, for passing criteria of 3 %/3 mm. Some-
times, the dose tolerance for dose points below 0.5 Gy
was increased by 10 % to 15 %.
We irradiated all plans in air using a static couch DQA
procedure with the couch positioned out of the gantry
bore. We collected the detector raw data and measured
the actual LOTs from them. We calculated the dose dis-
tributions from the expected and actual LOTs (named
hereafter expected and actual dose) in the patient’s plan-
ning images using Accuray’s standalone calculator [29].
Then, for each patient, we calculated the deviation be-
tween the expected and actual dose covering 95 % of the
PTV (D95). Finally, we calculated the correlation be-
tween the mean relative LOT discrepancy and the D95
deviation.
For each plan, we calculated the local 3D γ-index in
VeriSoft, suppressing points below 10 % of the dose max-
imum as recommended in the AAPM TG 218 report
[30]. VeriSoft does not provide an absolute dose differ-
ence threshold. We calculated the pass rates for passing
criteria of 2 %/2 mm and 3 %/3 mm. We calculated
the correlation between the γ-index pass rates and the
absolute dose (D95) deviation in the PTV.
We did not perform the clinical DQA ourselves. We
used the dose measured in the Octavius phantom during
the actual pretreatment DQA procedure. The γ-index
calculation parameters and passing criteria used to clin-
ically accept the plans were different from the ones used
in this study. In particular, we used a local γ-index ex-
pecting a higher sensitivity [11]. Stasi et al. [8] reported
a stronger correlation of the dose deviation with the local
γ-index pass rate than with the global pass rate. Clini-
cal DQA and in air LOT measurements relate to different
runs of the same plan. They were usually performed on
different days, but always within a fortnight.
III. RESULTS
A. Modified TomoPhant plans
As mentionned, “reference” and “expected” LOTs re-
fer to original and modified TomoPhant plans, respec-
tively. “actual” LOTs refer to the leaf open times mea-
sured from the detector raw data (section II B).
Figure 2 shows the means and the standard devia-
tions of the relative discrepancies between actual and
expected LOTs (actual-expected). The absolute discrep-
ancies means were 2 ms on TOMO1 and 0 ms on TOMO2
(equals in all 14 runs).
Figure 3 shows the means of the expected (expected-
reference) and actual (actual-reference) relative LOT dis-
crepancies. The difference between actual and expected
values is 1 % on TOMO1 and 0 % on TOMO2 (as in
figure 2).
The relative difference between the dose calculated
from the actual LOTs and the dose measured with ion-
isation chambers was of 0.2 ± 0.3 % on TOMO1 and of
4FIG. 2. Means (plain) and standard deviations (dashed) of
the relative differences between actual and expected leaf open
times (N = 14 on both units). The whiskers length equals
1.5 times the interquartile range (IQR).
TABLE I. Correlations between γ-index pass rate and abso-
lute dose deviation in the PTV (D95).
TOMO1 TOMO2
Tolerances Corr. (p-value) Corr. (p-value)
2 %/2 mm -0.23 (0.045) 0.09 (0.450)
3 %/3 mm -0.10 (0.396) 0.14 (0.222)
0.1±0.3 % on TOMO2 (N = 28, one standard deviation).
Figure 4 shows the relative difference between calculated
and measured dose.
Finally, the correlation between the mean relative ac-
tual LOT discrepancy and the relative dose difference
(measured-reference) was of 1.0 on both units (figure 5).
In this context, the reference dose is the planned dose of
the original (unmodified) TomoPhant plan.
B. Clinical pretreatment DQA
The means of the relative leaf open time discrepan-
cies ranged between −3.0 % and −0.8 % on TOMO1 and
−1.1 % and 1.4 % on TOMO2. The deviations of the
PTV dose (D95) ranged between −1.6 % and 0.0 % on
TOMO1 and −0.2 % and 2.4 % on TOMO2 The corre-
lation between mean relative LOT discrepancy and dose
the deviation in the PTV were of 0.76 (p ≈ 10−15) on
TOMO1 and 0.65 (p ≈ 10−10) on TOMO2 (figure 6).
The correlation between γ-index pass rate for accep-
tance criteria of 2 %/2 mm and 3 %/3 mm and absolute
dose deviation in the PTV (D95) are reported in table I
and figure 7.
IV. DISCUSSION
Here we validated a DQA method for tomotherapy
based on the LOT measurement. We generated LOT
discrepancies in TomoPhant plans and assessed that the
algorithm detected them. We checked that the dose cal-
culated from the measured LOTs was correct by compar-
ing it to ion chamber measurements. Finally, we evalu-
ated the impact of LOT discrepancies on clinical plans
and showed how the mean relative LOT discrepancy cor-
relates with the dose deviation in the PTV.
The actual (measured) LOTs corresponded well with
the planned LOTs (figure 2). We expected a 0 % mean
LOT difference, because in the TomoPhant plans most
LOTs fall within the linear regime of the leaves. 1 %
mean difference corresponded to 2 ms in this case. This
is below the LINAC pulse rate (300 Hz). The difference
between both units is notable. These results give us again
a good confidence in the LOT measurement algorithm
(see also [28]). The LOT differences standard deviations
(figure 2) gives an estimate of the intrinsic variability of
the LOTs (i.e. the real error of the MLC).
The algorithm detected correctly the MLC discrepan-
cies. The mean LOT discrepancy measured in the modi-
fied TomoPhant plans correspond to the expected values
within 1 % (figure 3).
The dose calculated from the actual LOTs was ac-
curate. The ion chamber measurements corresponded
within 1 % to the calculation (figure 4). As Accuray’s
standalone dose calculator was previously validated [29],
an accurate dose measurement implies that the calcula-
tion parameters – the LOTs – are accurate.
The mean relative LOT discrepancy is a good indicator
of the dose discrepancy (figure 6). On the TomoPhant
plans, it was even a perfect indicator (figure 5). It could
be perfected by weighting the discrepancies by the jaw
output factor, the leaf output factor, and the beam lat-
eral profile. But we wanted to provide an operational
value, not to recalculate a fluence map.
A mean relative LOT discrepancy between −3 % and
1 % did not lead to clinically relevant dose deviations
in the PTV (figure 6). Out of this range, a lack of
PTV coverage or hotspots in the patient’s organs at risk
(OARs) are to be expected. For that, the dose calcula-
tion from the measured LOTs brings a real added value.
We used Accuray’s standalone calculator, but any inde-
pendent dose calculation software (e.g. a Monte-Carlo
based one) would do the job.
Deshpande et al. [25] have also reported a linear rela-
tion between the dose deviation in the PTV and the mean
relative LOT difference. Though, they found steeper dose
deviations than we did. In particular, at a mean LOT
difference of 2 %, they reported a dose change of 5 %,
whereas we reported a dose change of 1 %. It is not clear
if they defined the mean relative LOT discrepancy the
same way we did.
The lack of correlation between the γ-index pass rate
and the dose to the PTV has already been documented
5FIG. 3. Means of the expected (black) and actual (grey) relative leaf open time discrepancies per TomoPhant plan. “ref” refers
to the original plan. The other values refer to the plans with modified leaf open times. They are two actual values per plan
because each measurement was run twice.
FIG. 4. Relative difference between calculated and measured dose per TomoPhant plan. The dose was calculated from the
actual (measured) LOTs. “ref” refers to the original plan. The other values refer to the plans with modified leaf open times.
They are two values per plan and chamber because each measurement was run twice. The ion chambers were at −0.5 cm (IC0)
and 8.0 cm (IC1) along the left-right axis (RTOG frame of reference) in the Cheese Phantom.
[7–15]. This highlights the lack of uniformity in the
applied passing criteria. With the criteria used in the
present study, the pass rate of many plans was below
90 % (figure 7), meaning the plans would have been re-
jected. Yet, all plans were accepted, which was the cor-
rect decision regarding the slight dose deviations in the
PTV (figure 6). The dose calculation shows that the
plans were actually of good quality. This study provides
a more clinically relevant DQA tool by relating directly
the plan quality indicator – the mean relative LOT dis-
crepancy – to the dose deviation in the PTV.
We previously reported that the LOT measurement al-
gorithm works as well in air as in vivo [28]. Thus, the
method proposed here would be also valid in vivo. In
fact, the LOTs of the TomoPhant plans were measured
while the phantom was in the beam path. Yet, we do
not recommend to drop pretreatment DQA. Suboptimal
use of the planning parameters (the pitch in particular)
can lead to non-negligible dose discrepancy [22, 31]. But
this makes the DQA method presented here easy to com-
mission. And it allows to monitor the MLC health on
the long run. The results on the TomoPhant show that
the LOT discrepancy pattern of a specific plan is repro-
ducible. Handsfield et al. [19] reached the same conclu-
sion. They measured in vivo the mean LOT difference
at all fractions of 10 patients’ treatment.
V. CONCLUSION
This study presented a DQA method based on the
LOTs measurement and the calculation of the actual dose
on the patient’s planning CT. We validated the method
by ion chambers measurements. We assessed the corre-
6FIG. 5. Mean relative (actual) leaf open time discrepancy
and relative difference between measured and reference dose
of the TomoPhant plans delivered on TOMO1 (black) and
TOMO2 (grey).
FIG. 6. Mean relative leaf open time discrepancy and devi-
ation between expected and actual PTV dose (D95) of the
plans delivered on TOMO1 (black) and TOMO2 (grey).
lation of the LOT discrepancy and the dose deviation in
the PTV, thus showing that the mean relative LOT dis-
crepancy is a reliable and clinically relevant indicator of
the plan quality.
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